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Abstract
Hemolytic uremic syndrome (HUS) is defined by the triad of mechanical hemolytic anemia, thrombocytopenia and
renal impairment. Atypical HUS (aHUS) defines non Shiga-toxin-HUS and even if some authors include secondary
aHUS due to Streptococcus pneumoniae or other causes, aHUS designates a primary disease due to a disorder in
complement alternative pathway regulation. Atypical HUS represents 5 -10% of HUS in children, but the majority of
HUS in adults. The incidence of complement-aHUS is not known precisely. However, more than 1000 aHUS
patients investigated for complement abnormalities have been reported. Onset is from the neonatal period to the
adult age. Most patients present with hemolytic anemia, thrombocytopenia and renal failure and 20% have extra
renal manifestations. Two to 10% die and one third progress to end-stage renal failure at first episode. Half of
patients have relapses. Mutations in the genes encoding complement regulatory proteins factor H, membrane
cofactor protein (MCP), factor I or thrombomodulin have been demonstrated in 20-30%, 5-15%, 4-10% and 3-5% of
patients respectively, and mutations in the genes of C3 convertase proteins, C3 and factor B, in 2-10% and 1-4%. In
addition, 6-10% of patients have anti-factor H antibodies. Diagnosis of aHUS relies on 1) No associated disease 2)
No criteria for Shigatoxin-HUS (stool culture and PCR for Shiga-toxins; serology for anti-lipopolysaccharides
antibodies) 3) No criteria for thrombotic thrombocytopenic purpura (serum ADAMTS 13 activity > 10%).
Investigation of the complement system is required (C3, C4, factor H and factor I plasma concentration, MCP
expression on leukocytes and anti-factor H antibodies; genetic screening to identify risk factors). The disease is
familial in approximately 20% of pedigrees, with an autosomal recessive or dominant mode of transmission. As
penetrance of the disease is 50%, genetic counseling is difficult. Plasmatherapy has been first line treatment until
presently, without unquestionable demonstration of efficiency. There is a high risk of post-transplant recurrence,
except in MCP-HUS. Case reports and two phase II trials show an impressive efficacy of the complement C5
blocker eculizumab, suggesting it will be the next standard of care. Except for patients treated by intensive
plasmatherapy or eculizumab, the worst prognosis is in factor H-HUS, as mortality can reach 20% and 50% of
survivors do not recover renal function. Half of factor I-HUS progress to end-stage renal failure. Conversely, most
patients with MCP-HUS have preserved renal function. Anti-factor H antibodies-HUS has favourable outcome if
treated early.
Keywords: Atypical hemolytic uremic syndrome, C3, factor H, factor I, factor B, membrane cofactor protein, thrombo-
modulin, plasma infusion, plasma exchange, eculizumab, kidney transplantation, combined liver-kidney transplantation
Disease name and synonyms
A classification of hemolytic uremic syndrome (HUS)
and thrombotic thrombocytopenic purpura (TTP)–the
two main variants of thrombotic microangiopathies
(TMA)-and related disorders according to etiology has
been proposed by the European Pediatric Research
Group for HUS [1]. In common medical language, the
names typical or post-diarrheal (D+) HUS describe the
most frequent form of HUS in children, due to Shiga-
toxin (Stx) producing Escherichia coli (STEC), mostly E
coli 0157:H7. By opposition, the name atypical HUS
(aHUS) has been historically used to describe any HUS
not due to STEC, thus including:
i) “Secondary” aHUS, due to a variety of causes, includ-
ing infectious agents different from STEC, mostly Strep-
tococcus pneumoniae (S pneumoniae) (via neuraminidase
of S pneumoniae and T antigen exposure), human immu-
nodeficiency virus and H1N1 influenza A, malignancy,
cancer chemotherapy and ionizing radiation, bone mar-
row or solid organ transplantation, calcineurin inhibitors,
* Correspondence: chantal.loirat@rdb.aphp.fr
1Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré; Université
Paris VII; Pediatric Nephrology Department; Paris, France
Full list of author information is available at the end of the article
Loirat and Frémeaux-Bacchi Orphanet Journal of Rare Diseases 2011, 6:60
http://www.ojrd.com/content/6/1/60
© 2011 Loirat and Frémeaux-Bacchi; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.sirolimus or anti vascular endothelial growth factor
(VEGF) agents, pregnancy, HELLP (Hemolytic anemia,
elevated Liver enzymes, and Low Platelets) syndrome,
malignant hypertension, glomerulopathies, systemic dis-
eases (systemic lupus erythematous and antiphospholipid
antibody syndrome, sclerodermia) or, in children, methyl
malonic aciduria with homocystinuria, cblC type, a rare
hereditary defect of cobalamine metabolism [1-14]. Of
note, it is now acknowledged that using the aHUS termi-
nology rather than an etiological-based denomination
(e.g. S pneumoniae-HUS) is inadequate [1].
ii) aHUS classified as “primary”, at least until the years
2000, as no exogenous cause was identified and the
mechanism was unknown. However, it was recognized
nearly four decades ago that this form of HUS could be
familial, touching members of the family several years
apart [15]. This is why it is also described as hereditary
HUS. During the last decade, this form of aHUS has been
demonstrated to be a disease of complement dysregula-
tion. Therefore it is now described as “complement dys-
regulation -associated aHUS” or, for abbreviation,
“complement-HUS”. Of note, most authors, including our-
selves for this review, now use the aHUS denomination to
designate only complement-HUS [16].
Another denomination for aHUS has been non-post-
diarrheal (D-) HUS, because the prodromal bloody diarrhea
characteristic of STEC-HUS was rarely the predominant
symptom. However, as gastroenteritis is a frequent trigger
of complement-HUS episodes [17,18], this terminology of
(D-) HUS should be withdrawn. In practice, some publica-
tions on (D-) HUS/aHUS in children include S pneumoniae
- HUS, a frequent category in children [19]. Also, some
publications on complement-HUS include some secondary
aHUS [18,20], while others exclude the various causes indi-
cated above (except pregnancy and contraceptive pill)
[17,21-23]. This may explain differences in results. Last, as
HUS and TTP share in common hemolytic anemia and
thrombocytopenia, with predominant central nervous sys-
t e m( C N S )i n v o l v e m e n ti nTTP and predominant renal
involvement in HUS, both diseases are often grouped
under the denomination TTP/HUS. This is also due to the
possible overlap of symptoms, with CNS involvement in
HUS and renal involvement in TTP. TTP and aHUS can
now be differentiated according to their different physio-
pathology i.e. deficiency of the von Willebrand cleaving
protease, ADAMTS (A Disintegrin And Metalloprotease
with ThromboSpondin type 1 repeats) 13, in TTP (com-
monly acquired via circulating autoantibodies in adults and
rarely inherited (Upshaw-Schulman syndrome) via reces-
sive ADAMTS-13 mutations in neonates or young chil-
dren) and complement dysregulation in aHUS. However,
biological investigations may not confirm the clinical diag-
nosis as at least 10-25% of TTP patients have normal
ADAMTS13 activity and 30% of aHUS patients have no
complement anomalies, suggesting the presence of
unknown physiopathological mechanisms [16,24,25].
Definition
HUS is defined by the triad of mechanical, non-immune
(negative Coombs test, except false positivity in Sp n e u -
moniae-HUS, see section Differential diagnosis) hemoly-
tic anemia (hemoglobin < 10 g/dL) with fragmented
erythrocytes (schizocytes), thrombocytopenia (platelets <
150.000/mm
3) and renal impairment (serum creatinine
> upper limit of normal for age). High lactate deshydro-
genase (LDH) and undetectable haptoglobin levels con-
firm intra vascular hemolysis. The underlying
histological lesion is TMA, characterized by thickening
of arteriole and capillary walls, with prominent endothe-
lial damage (swelling and detachment), subendothelial
accumulation of proteins and cell debris, and fibrin and
platelet-rich thrombi obstructing vessel lumina. TMA
predominantly affects the renal microvasculature,
although the brain, heart, lungs and gastrointestinal
tract may be involved. When none of the etiologies indi-
cated in the preceding chapter is present, the diagnosis
of primary aHUS, now demonstrated to be a disease of
complement dysregulation, is most probable. Our aim is
to review the tremendous progress performed during
the last decade in the understanding of this disease, and
to show how this new knowledge has opened the way to
new therapies.
Epidemiology
The incidence of aHUS is estimated in the USA to 2 per
million, a number calculated from the incidence of (D-)
HUS in children, including Sp n e u m o n i a e- HUS [19]. In
reality, the incidence of complement-aHUS is not known
precisely. However, more than 1000 aHUS patients inves-
tigated for complement abnormalities have been reported
from five European registries or series [17,18,20-22,26-28]
and one from the USA [23].
Clinical Description
Gender and age at onset
aHUS is equally frequent in boys and girls when onset
occurs during childhood [17], while there is a female pre-
ponderance in adults [20]. aHUS occurs at any age, from
the neonatal period to the adult age (extremes: 1 day to
83 years [17,18]. Onset during childhood (≤ 18 years)
appears slightly more frequent than during adulthood
(approximately 60% and 40% respectively) [18,21].
Seventy per cent of children have the first episode of the
disease before the age of 2 years and approximately 25%
before the age of 6 months [17]. Therefore, onset before
the age of 6 months is strongly suggestive of aHUS, as
less than 5% of STEC-HUS occur in children less than 6
months [29,30] and personnal communication of Lisa
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Triggering events
An infectious event, mainly upper respiratory tract infec-
tion or diarrhea/gastroenteritis, triggers onset of aHUS in
at least half of patients [18], up to 80% in pediatric cohorts
[17,31]. Interestingly, diarrhea preceded aHUS in 23% and
28% of patients in the French pediatric [17] and the Italian
adult and pediatric [18] cohorts respectively, showing that
the classification of HUS as (D+) or (D-) may be mislead-
ing and that post-diarrheal onset does not eliminate the
d i a g n o s i so fa H U S .O t h e rt r i g g e r ss u c ha sv a r i c e l l a[ 3 2 ] ,
H1N1 influenza [6,33-35] and, interestingly, STEC-diar-
rhea [17,18,36,37] have been reported in patients who
were investigated for aHUS because of a fulminant course,
a familial incidence of the disease or the subsequent
occurrence of relapses. Pregnancy is a frequent triggering
event in women [18,38,39]: 20% of women with aHUS
experience the disease, mostly the inaugural episode, at
pregnancy, 80% of them during the post-partum period
[39]. These observations highlight the difficulty to define
the limit between aHUS triggered by an incidental event
and secondary HUS.
Presenting features
Onset is generally sudden. Symptoms in young children
are pallor, general distress, poor feeding, vomiting, fatigue,
drowsiness and sometimes oedema. Adults complain of
fatigue and general distress. Most patients have the com-
plete triad of HUS at first biological investigation: hemo-
globin < 10 g/dL (not exceptionally as low as 3-4 g/dL),
platelets count < 150 000/mm
3 (generally between 30 000
and 60 000/mm
3, with no or little risk of bleeding compli-
cations), and renal insufficiency (serum creatinine > nor-
mal value for age), with or without anuria or reduced
urine volume, proteinuria if diuresis is maintained. The
presence of schizocytes, undetectable haptoglobin and
high LDH levels confirm the microangiopathic intravascu-
lar origin of hemolysis. If diagnosis is delayed, life-threa-
tening hyperkaliemia (≥ 6 mmol/L), acidosis (serum
bicarbonates < 15 mmol/L) and volume overload with
arterial hypertension and hyponatremia (< 125 mmol/L)
may be observed. Arterial hypertension is frequent and
often severe, due both to volume overload in case of oli-
guria/anuria and to hyperreninemia secondary to renal
TMA. Cardiac failure or neurological complications (sei-
zures) due to hypertension are possible. Half of children
and the majority of adults need dialysis at admission.
Extra renal manifestations are observed in 20% of
patients [17,18]. The most frequent is CNS involvement
(10% of patients) manifested by irritability, drowsiness, sei-
zures, diplopia, cortical blindness, hemiparesis or hemiple-
gia, stupor, coma. Brain magnetic resonance imaging
(MRI) is useful to differenciate CNS complications due to
arterial hypertension (reversible posterior leukoencephalo-
pathy syndrome with posterior white matter hyper inten-
sity predominant in the parieto-occipital regions) and
those due to cerebral TMA (on FLAIR and T2 sequences,
bilateral and symetrical hyperintensities of the basal gang-
lia, cerebral pedunculas, caudate nuclei, putamens, tha-
lami, hippocampi, insulae and possibly brainstem [40].
Myocardial infarction due to cardiac microangiopathy has
been reported in approximately 3% of patients and
explains cases of sudden death [18,41]. Distal ischemic
gangrene leading to amputation of fingers and toes can
also occur [42]. Approximately 5% of patients present with
a life-threatening multivisceral failure due to diffuse TMA,
with CNS manifestations, cardiac ischemic events, pul-
monary hemorrhage and failure, pancreatitis, hepatic cyto-
lysis, intestinal bleeding [17,18].
Some patients (approximately 20% of children [17] and a
similar percentage in adults) have a progressive onset with
subclinical anemia and fluctuating thrombocytopenia
during weeks or months and preserved renal function at
diagnosis. They may go to remission and subsequently
have an acute relapse, or they develop progressive hyper-
tension, proteinuria that may induce nephrotic syndrome,
and increase of serum creatinine over several weeks or
months. Some patients have no anemia or thrombocytope-
nia and the only manifestations of renal TMA are arterial
hypertension, proteinuria and a progressive increase of
serum creatinine.
In children, age, clinical context and symptoms at
presentation most often allow to differenciate patients as
having TTP or HUS, and, if HUS most likely, as having
post-diarrheal STEC-HUS, invasive S pneumoniae infec-
tion or complement-HUS. On the opposite, clinical
presentation is more confusing in adults and complement-
HUS has to be suspected whatever the clinical context.
Pathogenesis
As early as 1970-1980, it had been noticed that some
patients with aHUS had low C3 plasma levels [43].
Impressive progress has been done during the last decade,
showing that 4 regulatory proteins of the complement
alternative pathway, complement factor H (CFH), mem-
brane cofactor protein (MCP or CD46), factor I (CFI) and
thrombomodulin (THBD) and 2 proteins of the C3 con-
vertase, C3 and factor B (CFB), had a role in the pathogen-
esis of aHUS.
Complement and its regulation
Complement is the main system for defense against bac-
teria. It is activated by three pathways: the classical
pathway, the lectin pathway and the alternative pathway
[44] (Figure 1). These three pathways converge at the
point of cleavage of C3. While the activation of the
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immune complexes or microorganisms respectively, the
alternative pathway is continually activated and gener-
ates C3b which binds indiscriminately to pathogens and
host cells. On a foreign surface, such as a bacterium,
C3b binds CFB, which is then cleaved by Factor D to
f o r mt h eC 3c o n v e r t a s eC 3 b B b .T h eC 3 b B bp r o d u c e s
exponential cleavage of C3 (amplification loop) and the
formation of the C5 convertase (C3bBb(C3b)n). C5b
component, generated by C5 cleavage, participates in
the assembly of the membrane-attack complex (MAC)
C5b9, which induces opsonization, phagocytosis and
lysis of bacteria (Figure 1). This reaction is normally
strictly controlled at the host cell surfaces, which are
protected from the local amplification of C3b deposits
by several complement regulatory proteins: CFH (a
plasma glycoprotein, cofactor for CFI), CFI (a plasma
serine protease which cleaves and inactivates C3b to
form iC3b in the presence of cofactors, including MCP
(a non-circulating glycoprotein anchored in all cell
membranes except red blood cells), and possibly THBD,
an endothelial glycoprotein with anticoagulant, anti-
inflammatory, and cytoprotective properties but also a
regulator of the complement system [45]. In the pre-
sence of CFH, the competition between CFH and CFB
binding to C3b also limits the formation of the C3 con-
vertase. When CFH is bound to the C3b attached on
cell surface, CFB can no longer form the C3 convertase
(Figure 2).
CFH is the most important protein for the regulation of
the alternative pathway. CFH consists of 20 short consen-
sus repeats (SCRs) (Figure 3) and contains at least two
C3b-binding sites. The first binding site to C3b, which reg-
ulates fluid phase alternative pathway amplification, is
located within the N-terminal SCR1-4. The second C3b-
binding site is located in SCR19-20, in the C-terminal
Figure 1 The 3 pathways of complement activation. Classical, lectin and alternative pathways converge at the point of C3 activation. The
lytic pathway then leads to the assembly of the membrane attack complex which destroys infectious agents. Regulators of the alternative
pathway CFH, CFI and MCP cooperate to inactivate endothelial cell surface-bound C3b, thus protecting endothelial cells from complement
attack. CFH: factor H; CFI: factor I; CFB: factor B; CFD: factor D; MCP: membrane cofactor protein.
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SCR7 and SCR19-20. Endothelial cells are rich in polya-
nionic molecules e.g. glycosaminoglycans. The protection
of the host cells depends on the inactivation of surface-
b o u n dC 3 bs e c o n d a r yt ot h eb i n d i n go ft h eC F Ht ot h e
surface-bound C3b. All recent studies clearly demonstrate
the role of SCR19-20 in the protection of endothelial cells
[46-48]. The four proteins CFH, CFI, MCP and THBD
cooperate locally to cleave C3b to an inactive molecule
(iC3b). It has been proposed that the mutations identified
in aHUS patients in the genes CFH, MCP, CFI and THBD
induce a defect of the protection of endothelial cells
towards complement activation [46,49-51]. Altogether, all
identified genetic defects end up in an amplified genera-
tion of C3 convertase and secondarily the generation of
C5 convertase and thus the cleavage of C5. This results in
increased liberation of C5a and MAC at the endothelial
cell surface, causing additional endothelial cell damage
with exposure of the subendothelial matrix and thrombus
formation. This produces platelet consumption and red
Figure 2 Regulated and deregulated activation of the alternative complement pathway. Figure and comments reproduced from Zuber et
al [131]. a) CFH competes with CFB to bind C3b, which hampers the generation of C3 convertase. CFH binds to glycosaminoglycans on the
endothelial surface and factors, such as MCP, can act as a cofactor for the CFI-mediated cleavage of C3b to generate iC3b (inactivated C3b).
THBD binds to C3b and CFH and might accelerate the CFI-mediated inactivation of C3b. b) Uncontrolled activation of the alternative
complement pathway leads to the generation of the membrane-attack complex (C5b-9) through the actions of CFB, CFD and through the
generation of C3 convertase and C5 convertase. The resulting injury and activation of endothelial cells initiates a microangiopathic thrombotic
process. CFH: factor H; CFI: factor I; CFB: factor B; CFD: factor D; MCP: membrane cofactor protein; THBD: thrombomodulin.
Membrane
polyanions
C3b
Fixation to endothelial cells
Regulation of the activation of the alternative pathway
Figure 3 Factor H. Factor H is constituted by 20 short consensus
repeats (SCR). The two binding sites for C3b are in SCR 1-4 and 19-
20. The binding sites for polyanions of cell surface (vascular
endothelium) are in SCR 7 and 19-20. SCR 1-4 are involved in the
binding of CFH to circulating C3b i.e. the regulation of complement
alternative pathway activation in the fluid phase. SCR 7 and 19-20
are involved in the binding of CFH to polyanionic surface-bound
C3b i.e. the regulation of complement alternative pathway
activation at the endothelial cell surface.
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cells (inflammation, apoptosis) may participate actively to
this mechanism. In addition, a prominent role of CFH in
modulating platelet structure and function has been
demonstrated [52,53]. C-terminal CFH mutants have a
reduced ability to bind to platelets, resulting in comple-
ment activation on the surface of platelets. This in turn
causes platelet activation and aggregation and release of
tissue-factor expressing microparticules and participates to
the formation of thrombi within the microcirculation [52].
This physiopathological model is corroborated by trans-
genic animal models. Mice which express CFH variant
lacking the C-terminal 16-20 domain develop HUS similar
to the human disease, including TMA glomerular lesions
[54]. In this mouse model, CFH regulates C3 activation in
the plasma, but fails to bind to endothelial cells, similar to
mutant CFH of aHUS patients. Interestingly, this mouse
model permitted to demonstrate the key role of comple-
ment C5 in the development of HUS. When these mice
were crossed with mice deficient in C5, a complete protec-
tion from glomerular injury and HUS was observed [55].
This demonstrates that activation of C5, probably by unre-
gulated production of C5 convertase, is essential for the
development of aHUS.
Complement dysregulation in aHUS
CFH mutations
They were the first identified. A decrease of plasma C3
level was first reported in 1973 in 5 patients with severe
HUS [43]. The association of aHUS with a low CFH
plasma level was then reported for the first time in 1981
[56]. However, it is only in 1998 that Warwicker et al, by
genetic study of 3 families, could establish the link
between aHUS and the RCA (regulators of complement
activation) locus in chromosome 1q32, where the genes of
CFH and MCP are located. The first candidate gene stu-
died was CFH, and a heterozygous mutation in SCR20
was first demonstrated [57]. Subsequently, several groups
showed that a number of patients with aHUS had, despite
normal plasma levels of CFH, mutations in CFH gene,
mainly in SCR19 and 20 [18,21,31,46]. Presently, more
than 100 different mutations of CFH have been identified
in adults and children with sporadic or familial HUS [58].
More than 50% of CFH mutations are in SCR20 [38].
Functional studies to analyse the interaction between CFH
and its ligands (C3b, glycosaminoglycans, heparin and
endothelial cells) frequently demonstrate alteration of the
binding of CFH19-20 mutants [50,59-61]. Some mutations
(named type 1 mutations) are associated with a quantita-
tive deficiency in CFH (decreased CFH plasma levels), but
many, including the majority of mutations in SCR19 and
20, are associated with normal plasma levels of CFH, the
mutant CFH being functionally deficient (type 2 muta-
tions). Last, CFH is in close proximity to the genes
CFHR1-5 encoding five CFH-related proteins (Figure 4).
CFH and CFH-Rs share a high degree of sequence identity,
which predisposes to complex rearrangements leading to
non-functional CFH, such as hybrid CFH which has lost
SCR19 and 20 due to the combination of the first 21 N-
terminal exons of CFH (encoding SCR1 to 18) and the 2
Genetic rearrangement between homologous regions
Hybrid CFH-CFHR1 gene Large deletion of CFHR1-CFHR3
9A polymorphism also found in healthy
controls
9Genetic particularity associated with the
presence of anti-CFH antibodies
9Not found in the normal population
9CFH is not functional
CFH CFHR3 CFHR1
Homologous sequences
CFHR4
CFH CFHR4 CFH CFHR4
Figure 4 Complement factor H-related (CFHR) genes and their abnormalities in atypical hemolytic uremic syndrome: genetic
rearrangements between CFH and contiguous genes CFHR1 and CFHR3 or deletion of CFHR1-R3.
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gous mutations can be observed. These patients have very
low C3 and CFH plasma concentrations. But most muta-
tions are heterozygous. Plasma C3 level is decreased in
30% to 50% of patients with heterozygous mutant CFH,
and more frequently in type 1 than in type 2 mutations.
C3 plasma level may be decreased while CFH level is nor-
mal and vice versa [18,31,64]. (Table 1 and Table 2).
Mutations in CFH are the most frequent genetic abnorm-
ality in aHUS patients as they account for 20 to 30% of
cases (Table 3) [18,23,31,50]. The frequency of hybrid
CFH is approximately 1-3% in aHUS patients screened
with CFH Multiplex Ligation dependent Probe Amplifica-
tion (MLPA) (see section Diagnostic methods) [18].
Anti-CFH autoantibodies
An acquired dysfunction of CFH due to anti-CFH anti-
bodies was first described in 2005 [65]. The anti-CFH
IgG bind to CFH SCR19 and 20 and thus inhibit CFH
binding to C3b and cell surfaces [66-68]. Ninety per
cent of patients with anti CFH-antibodies have a com-
plete deficiency of CFHR1 and CFHR3 associated to a
homozygous deletion of CFHR1 and CFHR3 (Figure 4),
suggesting that this deletion has a pathogenic role in the
development of anti-CFH autoantibodies [[27,37,69-71].
Patients with anti-CFH antibodies can also have muta-
tions [18,71]: out of 13 patients with anti-CFH antibo-
dies, 5 had mutations in CFH , CFI, MCP or C3 [71].
Plasma C3 concentration is decreased in 40 to 60% of
patients with anti-CFH antibodies [18,37], and is lower
in patients with high titers of anti-CFH IgG than in
those with moderate titers [37]. CFH plasma concentra-
tion was decreased at disease onset in 22% of patients
studied by Dragon-Durey et al, not correlated with anti-
CFH IgG titers [37] (Table 1 and Table 2). Overall, anti-
CFH antibodies account for approximately 6% of aHUS,
mainly in children (10-12% of aHUS in children) (Table
3) [18,37,71,72].
MCP mutations
Richards et al in 2003 were the first to report mutations
of MCP in seven aHUS patients from 3 families [73].
More than 40 different mutations in MCP have now
been identified in patients with aHUS [38,50,58,74]. The
mutant MCP has low C3b-binding and cofactor activity
[21,75]. Most of the mutations are heterozygous, some
are homozygous or compound heterozygous. Most
patients present a decreased expression of MCP on per-
ipheral leucocytes (granulocytes or mononuclear cells),
an important diagnostic test. Less frequently, the expres-
sion of MCP is normal, but the protein is dysfunctional.
Of note, we observed that MCP expression can be
decreased transiently at the acute phase of any type of
HUS, therefore this is not strictly synonymous of MCP-
HUS, unless the decrease persists after resolution of the
acute phase (unpublished data from V.Frémeaux-Bac-
chi). C3 levels in MCP-mutated patients are most often
normal, a logic issue as MCP mutations are not
expected to activate complement in the fluid phase.
However, decreased C3 concentrations have been
reported in up to 27% of patients from the Italian Regis-
try [18] (Table 1 and Table 2). It is likely that some of
the MCP-mutated patients with decreased C3 have
another mutation responsible of the activation of com-
plement in the fluid phase. MCP mutations are more
frequent in children than in adults [18] and account for
5-15% of aHUS patients (Table 3) [17,18,20,23].
CFI mutations
Mutations in CFI were first described in 2004 in 3
patients with aHUS [76]. Approximately 40 mutations in
CFI have been reported in patients with aHUS, all hetero-
zygous [28,58,77-79]. CFI mutations either induce a
default of secretion of the protein or disrupt its cofactor
activity, with altered degradation of C3b/C4b in the fluid
phase and on surfaces [28,78,79]. Plasma C3 concentra-
tion is decreased in 20-30% of patients and CFI concen-
tration in approximately one third of patients. C3 level
can be decreased while CFI level is normal or vice versa
[18,28,31,76] (Table 1 and Table 2). The frequency of
CFI mutations in aHUS patients varies from 4% to 10%
according to series. Thirty per cent of patients with CFI
mutations carry at least one additional known genetic
risk factor for aHUS [28].
CFB mutations
In 2007 and 2009, Goicoechea de Jorge et al [80] and
Roumenina et al [81] reported four heterozygous muta-
tions in CFB in aHUS-patients. These mutations are gain
of function mutations, ending-up in a “super-B” which
Table 1 Percentage of patients with decreased C3 plasma concentration in the various subgroups of atypical
hemolytic uremic syndrome
CFH
mutation
CFI
mutation
MCP
mutation
C3
mutation
CFB
mutation
THBD
mutation
Anti -CFH
Ab
None
Decreased C3
concentration
(< 2SD)
(% patients)
30-50% 20-30% 0-27% 70-80% 100% 50% 40-60% up to
20%
Normal C3 plasma concentration does not eliminate the presence of a mutation in the complement system or of anti- CFH antibodies. Conversely, decreased C3
level signs the presence of a complement abnormality.
CFH: factor H; CFI: factor I; MCP: membrane cofactor protein; CFB: factor B; THBD: thrombomodulin; Ab, antibodies.
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Page 7 of 30binds excessively to C3b and induces an increased stabi-
lity and activity of the C3 convertase, resistant to decay
by CFH, with enhanced formation of C5b-9 complexes
and deposition of C3-fragments at endothelial cell sur-
faces [81]. CFB-mutated patients exhibit a permanent
activation of the alternative pathway with very low C3.
Plasma CFB levels may be normal or low (Table 1 and
Table 2). Mutations in CFB are rare, accounting for only
1-4% of aHUS patients [18,23,31,81,82]
C3 mutations
Heterozygous mutations in C3 were first described in
2008 in 13 patients from 11 families [83]. Most C3
mutations induce a defect of the ability of C3 to bind to
regulatory protein MCP and are indirect gain of func-
tion mutations leading to an increased capacity for CFB
to bind to C3b and an increased formation of the C3
convertase. Plasma C3 levels are low in 70-80% of
patients (Table 1 and Table 2) [18,83,84].
Table 2 Plasma concentration of C3, C4, CFH, CFI and CFB and expression of MCP in the various subgroups of atypical
hemolytic uremic syndrome
Protein level or expression
C4 C3 CFH CFI CFB MCP
CFH mutation N Normal
(decreased)
Normal
(decreased)
Normal Normal
(decreased)
Normal
CFI mutation N Normal
(decreased)
Normal Normal
(decreased)
Normal
(decreased)
Normal
MCP mutation N Normal
(decreased)
Normal Normal Normal Decreased
(normal)
CFB mutation N Decreased Normal Normal Normal
(decreased)
Normal
C3 mutation N Decreased Normal Normal Normal
(decreased)
Normal
THBD mutation N Normal
or decreased
ND ND ND Normal
Anti-CFH Ab N Decreased
(normal)
Normal
(decreased)
Normal Normal
(decreased)
Normal
Very low C3 levels are observed in patients with homozygous CFH mutation (complete CFH deficiency) or compound heterozygous CFH mutation, and in patients
with CFB or C3 gain-of-function mutations. In most of the other patients, C3 concentration is mildly decreased or normal. Undetectable CFH concentrations are
observed only in patients with homozygous CFH mutation. Decreased CFH concentration can be observed in patients with heterozygous type 1 CFH mutation,
and during flares of anti-CFH antibodies-HUS. Decreased C4 plasma levels have been reported in zero to a few % of patients of the various subgroups [18].
“Normal” and “decreased” without brackets means most frequently normal or decreased, within brackets means possible but not frequent. “Normal or decreased”
without brackets means normal or decreased is equally frequent. CFH: factor H; CFI: factor I; MCP: membrane cofactor protein; CFB: factor B; THBD:
thrombomodulin; Ab, antibodies. ND: not documented.
Table 3 Main clinical characteristics of patients with atypical hemolytic uremic syndrome according to complement
abnormality
Gene or
subgroup
Frequency
in aHUS
Minimal age at
onset
Risk of death or ESRD at 1
st
episode or within < 1 y
Risk of
relapses
Risk of recurrence after
renal transplantation
Plasma therapy
indicated
Children Adults
CFH 20-30% Birth any
age
50-70% 50% 75-90% Yes
CFI 4 -10% Birth any
age
50% 10-30% 45-80% Yes
MCP 5 -15% > 1 y any
age
0-6% 70-90% < 20% Questionable
C3 2 -10% 7 m any
age
60% 50% 40-70% Yes
CFB 1-4% 1 m any
age
50% 3/3 not in
ESRD
100% Yes
THBD 3 -5% 6 m rare 50% 30% 1 patient Yes
Anti-CFH
Ab
6% Mostly 7-11 y 30-40% 40-60% Yes if high Ab titer Yes (+ IS)
CFH: factor H; CFI: factor I; MCP: membrane cofactor protein; CFB: factor B; THBD: thrombomodulin; Ab, antibodies; ESRD: end stage renal disease; IS:
immunosuppressive treatment.
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Page 8 of 30C3 mutations account for 2 to 10% of aHUS patients
(Table 3) [18,23,83]
Thrombomodulin mutations
Recently, heterozygous mutations in THBD have been
demonstrated in 13 patients from the Italian cohort
[18,45]. In vitro, THBD binds to C3b and CFH and nega-
tively regulates complement by accelerating CFI-mediated
inactivation of C3b in the presence of cofactors CFH or
C4b- binding protein. The authors could demonstrate that
the THBD variants were less effective than wild-type
THBD in enhancing CFI-mediated inactivation of C3b.
Cells expressing mutant THBD have a reduced capacity to
degrade C3b and to generate thrombin-activable fibrinoly-
sis inhibitor that cleaves C3a and C5a. C3 levels are
decreased in half of THBD-mutated patients (Table 1).
THBD mutations account for 3% and 5% of aHUS
patients in the USA [23] and Italian [18,45] registries
respectively.
Combined mutations
Up to 12% of aHUS patients have various combinations
o f2o rm o r em u t a t i o n so fCFH, CFI, MCP, C3, CFB or
THBD [18,23,28,31].
In conclusion
One or several abnormalities of the complement system
are presently demonstrated in 70% of children and adults
with aHUS, and 30% of aHUS remain unexplained today.
Not unexpectedly, the percentage of patients within the
various subgroups shows some variations over the years
according to countries and registries.
Familial aHUS, incomplete penetrance and genetic variability
A familial occurrence of the disease is observed in
approximately 20% of pedigrees [17,18]. In familial
aHUS, the disease has an autosomal recessive or domi-
nant pattern of inheritance. The absence of familial
history of HUS does not preclude the possibility of a
genetic transmission of the disease. Familial aHUS is
observed in patients with complement mutations but
also in the unexplained group.
The majority of complement mutations are heterozy-
gous in aHUS patients. De novo mutations are excep-
tional and the same mutation is almost constantly
present in one parent -generally healthy-of the propositus
[18]. Penetrance of complement-aHUS has been found to
be only approximately 50% as half of the family members
who carry the mutation do not present the disease by age
45 [20,50]. This has been observed for all mutations, i.e.
CFH, MCP, CFI [18,38,46,85], CFB [80], C3 [18,83,84]
and THBD [18,45]. The identified mutation therefore
appears as a risk factor to the disease rather than its
direct and unique cause. In addition, age at onset and
severity of the disease may vary among family members
with the same mutation (Figure 5). The role of various
polymorphisms as independent or additional susceptibil-
ity factors to aHUS has been demonstrated in the genes
encoding CFH [18,26,85-87], MCP [26,86], CFHR1 [88]
or C4b-BP [89]. These sequence variations in the human
g e n o m ea r em o s t l yc h a n g e so fas i n g l eb a s e( S i n g l e
Nucleotide Polymorphism, SNP), which can be associated
with a change of amino-acid in the protein, inducing a
partial gain or loss of function. More than 30 SNPs are
localized in the RCA locus. For instance, the frequency of
an haplotype of CFH (CFH gtgt), defined by 4 SNPs loca-
lized in SCR 1, 7, 11 and 16 and one haplotype of MCP
(MCP gggac) defined by 5 SNPs localised in the gene
promoter and the intronic MCP gene, was significantly
Death of uremia
at  24 y
HUS at 60 y
Recurrence and death
after transplantation
Healthy at 36 y
HUS at 4 m                                                      
Well under weekly plasma 
exchange at 5 y
HUS at 3 m                                
Death
HUS at 4 m 
ESRD
*
*
*
Family 1 Family 2
Figure 5 Mode of transmission and intrafamilial phenotype variability of atypical hemolytic uremic syndrome: example from two
families with heterozygous CFH mutation. CFH mutation: W1183R, SCR 20 (Family 1); W1183L, SCR 20 (Family 2). Notice i) the autosomal
dominant (Family 1) or recessive (Family 2) mode of inheritance of the disease ii) the intrafamilial phenotype variability and incomplete
penetrance in Family 1. Affected individuals are indicated with filled symbols. Deceased individuals are crossed. Carriers of the CFH mutation are
indicated by an asterisk. Courtesy of Professor G. Deschênes (Hôpital Robert Debré, Paris), with permission.
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Page 9 of 30increased in patients compared to normal controls. In
some families, it appeared that the proband had inherited
the complement mutation from one parent, and an allele
carrying the polymorphism of CFH and/or MCP from
the other parent, while the healthy mutation carriers did
not inherit the aHUS-associated CFH and MCP poly-
morphisms [26,85,86]. However, even when an unfavour-
able group of risk factors co-segregates, the disease may
not manifest until middle age, suggesting that a trigger
(such as infection or pregnancy) hypothetized to be an
endothelial cell insult, is required to initiate the disease
in individuals unable to control complement activation.
aHUS therefore appears as a multifactorial disease result-
ing from environmental events that initiate endothelial
damage and genetic factors (mutations and at risk poly-
morphisms) that determine progression of the disease.
In practice, it is impossible to forecast the risk of
occurrence of HUS in family members presenting the
same mutation as their proband. Another problem is that
several genetic anomalies may be present in one family,
some of them unknown. For example, in three families
from the French Pediatric Registry, one child with aHUS
had CFH or CFI mutation respectively, while his sibling
also with aHUS had no mutation [17 + unpublished data]
(Figure 6). This shows that other unidentified genetic risk
factors may be present in the patients and healthy family
members.
Genotype-phenotype correlations
Age at onset is similar in adults whatever the comple-
ment anomaly. On the opposite, it varies in children
according to complement anomaly [17,18]. In the French
pediatric cohort, very young age at onset was predomi-
nantly observed in patients with CFH (median 6 months,
from 3 days to 3.6 years) or CFI (median 2 months, from
1 day to 3.8 years) mutations, while onset before the age
of one year was not observed in children with MCP
mutations (median 4.6 years, from 1.6 to 11.3 years [17].
In patients from the Italian registry, the earliest onset
(between birth and 1 year) was in children with CFH, C3
or THBD mutations [18]. Thus, the majority of children
with CFH, CFI, C3 and THBD mutation start the disease
before 5 years of age. On the opposite, most children
with anti-CFH antibodies (median age 8.5 years, from 8
months to 14 years, most frequently 7 to 11 years) or
MCP mutations, and a few with THBD mutations, start
the disease during late childhood or adolescence (Table
3) [17,18,37]. Outcome and prognosis according to com-
plement abnormality are indicated in Sections Outcome
and Prognosis.
Diagnostic methods
Methods for complement investigation are indicated in
Table 4 and Table 5. Except for the concentration of
plasma C3 and C4, investigations of the complement sys-
tem require specialized laboratories [61]. The list of
laboratories providing specialized investigations of the
complement system is available in references [38,90].
Except for the study of MCP expression on peripheral leu-
cocytes and the screening for mutations, blood samples
must be collected before plasma infusion (PI) or plasma
exchange (PE). Normal range of each protein has to be
determined for each technique in each laboratory using
100 healthy donors of the same ethnicity as the patients. A
major issue is the lack of international standards for CFH
and CFI. In addition to physiological variability of plasma
CFH concentration, the dosage of CFH is particularly pro-
blematic, explaining variations of results between labora-
tories [61]. Assessment of plasma C3, C4, CFH, CFI and
CFB levels, membrane expression of MCP on blood leuco-
cytes, and screening for anti-CFH antibodies is mandatory
and results should be available as soon as possible.
In children, age at onset guides genetic investigations
(Table 6): in patients with onset before the age of one
year, CFH, CFI and C3 should be screened first, whether
C3 plasma concentration is decreased or not. If onset is
after one year of age and C3 concentration is normal,
MCP mutation should be first investigated. As anti-CFH
CFI G243D* No mutation No mutation
HUS at 8m HUS at day 3 HUS  at 8m
No mutation
HUS at 3m
CFI C453R*
* **
HUS at 3y
CFH A161S*
HUS at 5m
* * *
Figure 6 Unknown risk factor(s) to atypical hemolytic uremic syndrome can be associated with identified mutations: example from
three families. In the 3 families, one child with aHUS has a mutation in CFH or CFI while a sibling also with aHUS has no mutation identified.
Therefore the two siblings in each family share at least one unidentified risk factor. Affected individuals are indicated by filled symbols. Carrierso f
mutations are indicated by an asterisk. Courtesy of Professors R. Salomon (Hôpital Necker, Paris), E. Bérard (Hôpital de l’Archet, Nice) and G.
Deschênes (Hôpital Robert Debré, Paris), with permission.
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mately 7 years and in pre-adolescents and adolescents,
screening for anti-CFH antibodies is a priority at this age,
especially if C3 concentration is decreased. Screening for
CFB and THBD mutation is necessary in case no muta-
tion is found in CFH, CFI, MCP and C3,w h a t e v e rt h e
age of onset. Figure 7 shows genetic screening strategy
according to plasma levels of C3, CFH and CFI and
expression of MCP. This strategy is theoretically valid,
although not very realistic in practice.
Several messages are important: i. The association of
low C3 and normal C4 plasma levels signs complement
alternative pathway activation in the fluid phase. Very
low C3 and CFB levels are indicative of intense alterna-
tive pathway activation, mildly decreased C3 with nor-
mal CFB is indicative of mild activation in the fluid
phase. ii. Normal C3 and CFB levels do not eliminate a
complement abnormality with dysregulated activation at
the cell surface. iii. The assessment of complement
proteins plasma level is insufficient and genetic analyses
are necessary in any patient with aHUS, even if the
plasma level of C3, CFH, CFI and CFB and the expres-
sion of MCP are normal. iv. However, knowledge of
complement proteins plasma levels guides the investiga-
tor towards which gene to screen first (Figure 7) and
helps him for the validation of genetic screening. For
instance, if CFI level is low, and non CFI mutation is
found, results of sequencing are re-examined and if
necessary, sequencing repeated to find out the missed
mutation; if C3 is low with normal CFH anf CFI levels
and no anti-CFH antibodies, a C3 and then a CFB
mutation must be looked for; if a patient has MCP
mutation with low C3, a mutation in another factor
t h a nM C Pm u s tb el o o k e df o r .v .C 3a n dC F Hp l a s m a
levels are normal in patients with hybrid CFH detected
only by MLPA, a technique now indicated for all unex-
plained aHUS. vi. As mutations have been identified
everywhere in the various genes, screening of all exons
Table 4 Methods for assessment of plasma and membrane complement proteins and screening for anti- factor H
antibodies
Plasma or
membrane
complement
Proteins
Plasma
concentration
(mg/L) (- 2 to + 2
SD) or membrane
expression
Technique Laboratory Interpretation
C3 660-1250 Nephelometry Basic
complement
screen
Severe complement consumption through the alternative
pathway indicated by very low plasma levels of C3 and CFB.
Frequently, there is only an isolated moderate decrease of C3
level with normal CFB level
CFB 93-380 Nephelometry Specialized
diagnostic
CFH 330-680
(no international
standard)
ELISA Specialized
diagnostic
CFH or CFI less than 60% of normal are compatible with
quantitative deficiency
CFI 40-80
(no international
standard)
ELISA
(or radial
immunodiffusion)
Specialized
diagnostic
Anti-CFH Ab Screening ELISA Specialized
diagnostic
The title is expressed in Arbitrary Units (AU)
MCP Mean fluorescent
intensity (MFI)
FACS
(a) with anti- MCP
phycoerythrin -conjugated
antibodies
Specialized
diagnostic
No MCP expression is detected in patients with homozygous
MCP deficiency. The MFI in patients of heterozygous MCP
deficiency is around 50% of the normal range
(a) Usually performed on peripheral granulocytes or mononuclear cells in EDTA-blood sample.
Elisa, enzyme-linked immunosorbent assay; EDTA, ethylene diamine tetra-acetic acid; FACS, fluorescence-activated cell sorter.
Table 5 Genetic screening of the complement system
Gene Location Method of choice for mutation screening Number of exons
CFH RCA, Chr 1q32 Direct sequencing analysis 22
CFI Chr 4q25 Direct sequencing analysis 13
MCP RCA, Chr 1q32 Direct sequencing analysis 14
C3 Chr 19p13.3 Direct sequencing analysis 42
CFB Chr 6p21.3 Direct sequencing analysis 18
THBD Chr 20p11.2 Direct sequencing analysis 1
Chr, chromosome; CFH, factor H; CFHR1, factor H-related protein 1; CFI, factor I; MCP, membrane cofactor protein; CFB, factor B; THBD, thrombomodulin.
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tions in two or more complement regulators, and some
have a mutation in addition to anti-CFH antibodies, the
identification of a mutation or anti-CFH antibodies does
not preclude the necessity to study all genes, although
the specific role of each complement abnormality on the
outcome of the disease is unclear. viii. Screening for
mutations and anti-CFH antibodies is mandatory before
transplantation, especially in historical patients consid-
ered for transplantation (see Section Transplantation).
ix. The functional consequences of each genetic
abnormality should be determined in vitro by mutagen-
esis, if not already established [61]. Interaction between
the physician and the referent person in the specialized
laboratory about the pathogenicity (proven/most prob-
able/unlikely/unknown) of the mutation is fruitful and
should be encouraged.
Differential Diagnosis
Complement-aHUS has to be differenciated from other
forms of HUS and from TTP. Age at onset (Figure 8),
family history, context and clinical presentation are gen-
erally indicative in children, while presentation may be
more confusing in adults (Table 7). Biological confirma-
tion is now available for the majority of patients [90,91].
In neonates and children less than 6 months of age,
hereditary complement-HUS is the first line diagnosis,
but pneumococcal HUS also needs urgent recognition
and treatment [92-94], while hereditary congenital TTP
and methylmalonic aciduria, both exceptional diseases,
are alternative diagnoses that need specific investigations
and treatment. In children from 6 months to 5 years of
age, again the diagnosis of pneumococcal HUS must not
be delayed. Post-diarrheal STEC-HUS largely predomi-
nates in this age group, but complement-HUS comes
Table 6 Atypical hemolytic uremic syndrome in children: age at onset and plasma C3 concentration as indicators of
complement anomaly to screen in priority
Age at onset Complement abnormality to screen first
Birth to < 12 months ± decreased C3 CFH , CFI, C3 mutation
> 1 year + normal C3 MCP decreased expression/mutation
> 1 year + decreased C3 CFH, CFI, C3 mutation
7-11 years ± decreased C3 Anti-CFH antibodies
CFH: factor H; CFI: factor I; MCP: membrane cofactor protein
First step
- Screening  for STEC  Æ negativeÆ STEC-HUS unlikely
- ADAMTS 13 activity Æ normal Æ TTP eliminated
- C3, C4, CFB                Æ low C3 + normal C4 + low or normal CFB 
= complement alternative pathway activation 
- MCP expression on leucocytes Æ decreased Æ MCP  sequencingÆ MCP-HUS
- Anti-CFH antibodies Æ positive Æ anti-CFH antibodies-HUS
Second step
Decreased C3
No anti-CFH antibodies
Normal C3, CFH, CFI, MCP,
No anti-CFH antibodies or          
Decreased CFH
CFH  sequencing
+
Decreased CFI
+
CFI  sequencing
Normal CFH and CFI
+
C3 , CFH  and CFI  
sequencing, 
CFH, CFI, MCP, 
C3, CFB sequencing, 
CFH MLPA
Third step
Third step
Complete sequencingof all  risk factors (includingTHBD) even
if a mutation or anti-CFH antibodies have been found
First step
Figure 7 Complement system screening strategy in atypical hemolytic uremic syndrome. Knowledge of complement proteins plasma
concentrations guides the investigator for the choice of which gene to study first and for the validation of genetic screening. Of note i. C3 may
be low despite normal CFH or CFI plasma levels in patients with CFH or CFI mutations respectively. ii. C3 and CFH plasma levels are normal in
patients with hybrid CFH detected by MLPA. STEC: Shiga-toxin producing Escherichia coli; ADAMTS 13, A Desintegrin And Metalloproteinase with
a ThromboSpondin type 1 motif, member 13; CFH: factor H; CFI: factor I; CFB: factor B; MCP: membrane cofactor protein; THBD:
thrombomodulin.; MLPA, multiplex ligation dependent probe amplification.
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plement-HUS, predominantly MCP-HUS and anti-CFH
antibodies -HUS. Interestingly, it is also the age for
acquired TTP due to anti-ADAMTS13 antibodies [95]
(Figure 8). In adults, secondary aHUS or immune TTP
may have common causes such as autoimmune diseases
(systemic lupus erythematosus (SLE) or antiphospholipid
(APL) antibodies syndrome) (Figure 8). Pregnancy may
trigger both HUS and TTP, although pregnancy-TTP
mostly occurs during the second and third trimesters
w h i l ep r e g n a n c y - H U Si sm o s t l yad i s e a s eo ft h ep o s t -
partum [39]. TTP and aHUS generally have different
clinical presentation, with predominant neurologic
involvement in TTP and renal involvement in HUS, but
symptoms may overlap and complement-HUS has to be
suspected whenever ADAMTS13 deficiency is not con-
firmed in a TTP- patient.
Patients identified as having aHUS require full biological
investigation (Table 8)
i. Investigations for STEC infection at onset of HUS are
required in all patients, including those identified as
having aHUS, as unusual presentation of STEC-HUS
(unusual age or absence of diarrhea) can occur.
ii. ADAMTS13 activity determination is required in all
patients identified as having aHUS, as manifestations of
aHUS and TTP may overlap. In addition, the associa-
tion of CFH mutation with a hereditary complete defi-
ciency of ADAMTS13 has been reported [96]. Blood
must be collected before PI or PE. Only ADAMTS13
activity below 10% of normal is significant of TTP.
ADAMTS13 plasma concentration can now be deter-
mined within less than 24 hours by Elisa technic [97].
Laboratories for ADAMTS13 determination are indi-
cated in [38,90].
During pregnancy
Neonates-
<6m
Children
6m-5y
Pre-
adolescents-
adolescents
Adults Post-renal
transplantation
S pneumoniae
HUS
Anti-CFH Ab
HUS
Anti-
ADAMTS 13 
Ab TTP
HIV, malignancy , cancer 
chemotherapy, drugs,
malignant hypertension
Methyl malonic
aciduria Congenital TTP
Hereditary
ADAMTS13 
deficiency
Hereditary
Complement
HUS
STEC HUS
Post-partum Post-partum
Autoimmune/systemic disease
Bone marrow transplantation, glomerulopathies
Figure 8 The various subgroups of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura according to age at onset.
Pink arrows and boxes: complement-HUS; green arrows and boxes: TTP; upper line: immune HUS and TTP; lower line: hereditary HUS and TTP. The
figure also shows the 2 main infection-induced HUS (blue arrows and boxes) and the various causes of secondary atypical HUS (violet boxes),
according to age. HUS: hemolytic uremic syndrome; TTP: thrombotic thrombocytopenic purpura; HIV: human immunodeficiency virus; STEC: Shiga-
toxin producing Escherichia coli; ADAMTS 13, A Desintegrin And Metalloproteinase with a ThromboSpondin type 1 motif, member 13.
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Page 13 of 30Table 7 Clinical presentation of the various subgroups of hemolytic uremic syndrome and thrombotic
thrombocytopenic purpura and investigations to confirm diagnosis
Age at onset and clinical presentation Probable diagnosis Investigations to confirm diagnosis
Neonatal period
Severe jaundice
Porto colour urine without major hematuria
Consanguineous family and/or similar symptoms or neonatal
death in siblings
Congenital TTP
(Upshaw-Schulman
syndrome)
ADAMTS 13 deficiency (< 10%) without anti-ADAMTS 13
antibobies
Mutation in ADAMTS13 (autosomal recessive)
Neonatal period-< 6 months
Failure to thrive, feeding difficulties, hypotonia ± developmental
delay
Consanguineous family
Methyl-malonic
aciduria-associated
HUS
Hyperhomocysteinemia, hypomethioninemia, methyl-
malonic aciduria
Mutation in MMACHC (autosomal recessive)
< 2 years
Fever
Invasive S.pneumoniae infection (proven or suspected): pneumonia,
meningitis, septicaemia, especially if empyema or subdural
collection
HUS due to
Streptococcus
pneumoniae
False positive Coombs test
Positive cultures (blood, CSF) or PCR
Positive T-activation test (exposure of the Thomsen-
Friedenreich antigen on red blood cells) supports the
diagnosis
> 6 months-5 years
Diarrhea ± melena during the last 2 weeks
Endemic region of STEC or Shigella dysenteriae infection
STEC-HUS
(Shigella dysenteriae-
HUS in endemic
regions)
Stool or rectal swab: culture for STEC (Mac Conkey for
0157:H7); PCR for Stx
Serum: anti-LPS antibodies against the most common
serotypes in the local country
Adolescents and adults
Fever
Central nervous system manifestations
No or mild renal involvement
Autoimmune context (SLE, APLS, thyroiditis)
Immune TTP ADAMTS 13 deficiency (< 10%) with anti-ADAMTS13
antibodies
From birth to adolescence and adult age
No prodromic diarrhea or prodromic diarrhea but any of the
following:
- age < 6 months or > 5 years
- insidious onset
- relapse of HUS
- suspicion of previous HUS
- previous unexplained HUS
- post-transplant HUS
- pregnancy (post-partum) HUS
- non synchronous familial HUS
Complement-aHUS Complete investigation of the complement system
HUS, hemolytic uremic syndrome; TTP: thrombotic thrombocytopenic purpura; ADAMTS13: A Desintegrin And Metalloproteinase with a ThromboSpondin type 1
motif, member 13; MMACHC: methylmalonic aciduria and homocystinuria; CSF: cerebro-spinal fluid; PCR: polymerase chain reaction; STEC: Shiga-toxin producing
Escherichia coli; Stx: Shiga-like toxin; LPS: lipopolysaccharide
Table 8 Investigations recommended in patients identified as having atypical hemolytic uremic syndrome, adapted
from [90]
Investigations
1. STEC infection Stool or rectal swab: culture for STEC (Mac Conkey for 0157:H7); PCR for Stx
Serum: anti-LPS antibodies against the most common serotypes in the local country
2. Disorders of complement regulation C3, C4 (plasma/serum)
Factor H, Factor I, Factor B (plasma/serum)
Anti-factor H autoantibodies
MCP (surface expression on leucocytes (polynuclear or mononuclear leucocytes by FACS)
Gene mutation analysis in factor H, factor I, MCP, C3, factor B
3. ADAMTS13 deficiency
inherited or acquired classification
Plasma ADAMTS13 activity or dosage (Elisa) ± inhibitor
4. Cobalamin metabolism:methyl
malonic aciduria
Plasma amino-acid chromatography (high homocysteine, low methionine); urine organic acid
chromatography (methyl-malonic aciduria)
± mutation analysis in MMACHC gene
5. HIV Serology
6. Pregnancy, HELLP syndrome Pregancy test, liver enzymes. Investigate as in 2 and 3
7. Miscellaneous Antinuclear antibody, lupus anticoagulant, anti-phospholipid antibodies
STEC: Shiga-toxin producing Escherichia coli; Stx: Shiga-like toxin; PCR: polymerase chain reaction; ADAMTS13: A Desintegrin And Metalloproteinase with a
ThromboSpondin type 1 motif, member 13;HIV: human immunodeficiency virus; HELLP: Hemolysis, Elevated Liver enzymes, Low Platelet count; MCP: membrane
cofactor protein; FACS: fluorescence-activated cell sorter; MMACHC: methylmalonic aciduria and homocystinuria;
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(homocystinuria with methylmalonic aciduria) is manda-
tory in all children with aHUS. In the neonatal form of
this exceptional intra cellular vitamin B12 metabolism
anomaly, mortality is extremely high once HUS has
developed, because of multivisceral failure [12,14]. The
recommendation to perform diagnostic investigations for
this disease in all children with aHUS comes from the
report of a few cases of mild methylmalonic aciduria
without neurological involvement, revealed by aHUS dur-
ing late childhood. Such cases appear to have a favour-
able outcome both of HUS and the metabolic disease
under continuous B12 supplementation [13]. Of note, the
association of methylmalonic aciduria with MCP [98] or
CFH [99] mutation has been reported, once again outlin-
ing that aHUS is a multifactorial disease.
iv. In adults with aHUS, HIV infection and autoim-
mune disease must systematically be investigated.
v. Women with HELLP or post-partum HUS, and
patients with post-transplant HUS, require complement
investigation. While no complement dysfunction has been
demonstrated in patients with HIV-aHUS or HUS after
bone marrow transplantation, complement mutations
have been demonstrated in 36% of women with HELLP
syndrome [100], 86% of pregnancy-HUS [39] and 29% of
de novo HUS after kidney transplantation [101]. Of note,
complement mutations have also been demonstrated in
18% of patients with SLE and/or APL antibodies who
develop preeclampsia and 8.5% of preeclampsia patients
lacking autoimmune disease [102]. The frequency of pre-
existing complement anomalies in aHUS complicating
malignant hypertension has not been investigated.
Genetic Counselling and Prenatal Diagnosis
De novo mutations are exceptional and, if investigated,
one parent of the proband has the mutation. Proband’s
siblings and children have a 50% chance of inheriting the
mutation. However, as penetrance of the disease is
approximately 50% and age at onset and clinical severity
often variable among individuals with the same mutation
within a family, it is extremely difficult to predict the risk
of developing the disease and the outcome in the indivi-
duals at risk. Genetic counseling must also take into
account that HUS results from a panel of genetic risk fac-
tors, some known and some unknown. Identifying one
factor does not eliminate the responsibility of another
one, not known today. In other words, it is as difficult to
be sure that an individual has no risk of HUS as to be
sure he is at risk.
Despite these caveats, genetic counseling has to be
offered to parents and young adults with the disease or at
risk. Prenatal testing is possible. Identification of the muta-
tion(s) is necessary before prenatal testing is proposed. In
addition, the functional consequences of the mutation
need to be established, to be sure the mutation is at high
risk of being disease-causin g .H o w e v e r ,s i m i l a rt ow h a t
happens for healthy family members with the mutation,
the risk for the fetus to develop aHUS after birth is extre-
mely difficult to forecast, even for mutations with a high
degree of pathogenicity. Pre implantation genetic diagnosis
may be an option.
Management Including Treatment
Supportive treatment
Progress in intensive care and dialysis has contributed to
the decrease of mortality, especially in young children.
In practice, any patient suspected of having aHUS needs
to be transfered to a specialized centre (Nephrology or
if necessary Critical Care) where management of acute
renal failure and hypertension, the various techniques of
dialysis and plasma exchange (PE) are daily practice.
Although the scope of this review is not to develop the
management of acute renal failure, some specificities need
to be indicated: i. Platelets infusions are contra-indicated,
as they might worsen the TMA process, unless the patient
is bleeding (exceptional) or when a surgical procedure at
risk of being hemorrhagic is scheduled in a severely
thrombocytopenic patient (platelets < 30 000/mm
3). ii.
Vascular access most often rely on a central catheter
allowing dialysis and PE: the vein (femoral, subclavian or
internal jugular) depends on patient’s age and local prac-
tice. Percutaneous insertion of double lumen catheter has
to be performed by a trained physician. The protection of
peripheral and central veins (no ligation) is of outmost
importance in these patients who may need long term vas-
cular access for hemodialysis or PE.
Considering the frequency of relapses triggered by infec-
tions, clinicians should be vigilant for signs of infections
and treat them when appropriate. Whether vaccination
might trigger HUS is scarcely documented. The benefit of
vaccination, especially against influenza (seasonal and
H1N1, using the vaccine without adjuvant), most probably
outweighs its risk.
Plasmatherapy
Plasmatherapy remained the first line treatment of aHUS
until 2010, based on expert opinion rather than clinical
trials [31,90,91,103]. No prospective trial has been done.
Poor renal outcome in retrospective registries [17,18]
could be related to delayed, insufficient or too short plas-
matherapy. Viroinactivated fresh frozen plasma (FFP)
brings normal amount of CFH, CFI, CFB and C3. PE
removes mutant CFH, CFI, CFB and C3, anti-CFH antibo-
dies and other triggers of endothelial dysfunction and pla-
telet hyperaggregability, while volume restitution with FFP
brings the functional proteins. In addition, PE prevents
volume overload and cardiac failure when large amounts
of FFP are infused. It also prevents the hyperprotidemia
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several times a week.
Plasmatherapy in patients with CFH mutation
Overall, 63% of patients with CFH mutation who received
some form of plasmatherapy (plasma infusion or plasma
exchange) in the Italian Registry had a response to
plasma therapy (either complete or partial (hematological
remission with renal sequel). However, the percentage of
complete recovery under plasmatherapy was only 5% and
evolution to death or end stage renal disease 37% [18].
Twelve observations, mainly in children, show that early
intensive plasmatherapy can rescue HUS and long term
plasmatherapy prevent relapses and evolution to end
stage renal failure (ESRF) in CFH-mutated patients
[17,103-115]. These patients received PE (40-60 ml/kg
with FFP for restitution) or PI (10-15 ml/kg) at the acute
phase, most of them daily during at least 5 days and up
to 2 weeks, then tapered to long term maintenance plas-
matherapy (PE or PI from weekly to every 2 to 4 weeks).
Most of them had relapses during infections, rescued by
intensification of plasmatherapy. Ten of the twelve
patients had preserved kidney function after 1 to 6 years
follow-up under plasmatherapy, but two developed ESRF
after 4 years [107] and 7 years [115], showing that it is
uncertain whether the favourable effect of plasmatherapy
can be maintained for decades. On the opposite, most
patients who received plasmatherapy only during acute
episodes died or were in ESRF within less than one year
[103,113,116-118]. The response might be different
according to genotype. A few observations suggest that
PE could be superior to PI in patients with a dysfunc-
tional mutant CFH (type 2 mutations), possibly because
PE removes this dysfunctional CFH [113,114].
Plasmatherapy in patients with CFI mutation
Only 25% of patients with CFI mutation who received
plasmatherapy in the Italian Registry had a response and
75% progressed to death or ESRF [18]. Five CFI-mutated
patients (3 of them with associated risk factors) who
received PE or PI [36,77,103,119] at the acute phase had
complete or partial remission. All had relapses and all
except one developed ESRF within a few weeks or months.
A larger number of patients would be necessary to docu-
ment the effect of plasmatherapy in patients with CFI
mutations and the role of associated mutations in the
response to plasma therapy.
Plasmatherapy in patients with MCP mutation
As MCP is not a circulating protein, a beneficial effect of
plasmatherapy is unlikely to be expected in MCP-mutated
patients. At least ninety per cent of patients undergo remis-
sion from acute episodes, whether or not they receive plas-
matherapy [17,18,21]. However, PE is often performed
during flares of HUS, to clear up noxious factors such as
aggregating factors/triggers of endothelial lesions. Long-
term PE does not seem to be of benefit in MCP-HUS [120].
Plasmatherapy in patients with C3, CFB or THBD mutation
The benefit of plasmatherapy is scarcely documented in
these subgroups. Fivety seven per cent of C3-mutated
patients and 88% of THBD-mutated patients who
received plasmatherapy in the Italian Registry had a
response (either complete or partial remission (hemato-
logical remission with renal sequel), and 43% and 13%
respectively progressed to death or ESRF [18]. Remission
with PE or PI has been reported in 2 patients with C3
mutation [84,121] and 3 with CFB mutation [80-82].
Plasmatherapy and immunosuppressive drugs in aHUS with
anti-CFH antibodies
PE, to remove the antibodies, is first line treatment in
anti-CFH antibodies-HUS. However, antibodies titer
often reincreases after PE cessation and relapses of HUS
frequently occur. Therefore the association of immuno-
suppressive treatment is recommended, using steroids
and azathioprine, mycophenolate mofetil, intravenous
cyclophosphamide or anti-CD20 [37,68,72,122-124]. The
duration of plasmatherapy and the choice of the immu-
nosuppressive drug are not presently standardized. Both
should be guided by the evolution of anti-CFH antibodies
titer. High antibody titer is correlated with the risk of
relapses, which in turn increase the risk of renal sequels
[37].
Recommendations for the practice
Since complement and ADAMTS13 information is usually
not available when the patient presents with symptoms of
aHUS, expert opinion recommends empiric plasmatherapy
to be started as early as possible, within 24 h of presenta-
tion [90,91,125]. First line treatment should be PE, with
exchange of 1.5 plasma volume (60-75 ml/kg) per session,
replaced by FFP. When PE cannot be performed within
24 h of presentation, PI of 10-20 ml/kg should be given if
the patient is not volume overloaded and/or hypertensive
and does not show symptoms of cardiac failure.
PE should be performed daily until platelet count, LDH
and hemoglobin levels are normalized and renal function
clearly improving since several days. Persistence of hemo-
lysis or lack of improvement of renal function after 3-5
daily PE have to be regarded as criterium for uncontrolled
TMA even if platelet count has normalized (a fortiori if
thrombocytopenia persists), and as an indication to main-
tain daily PE or, in recent days, to switch the patient to
eculizumab (See section Complement inhibitors: the new
treatment in 2010-2011). When disease activity is con-
trolled by daily PE, recommended subsequent frequency
of PE/PI is five times a week for 2 weeks and three times a
week for the subsequent 2 weeks. Further frequency has to
be decided on a case by case basis, according to evolution
and to which risk factor is demonstrated. The demonstra-
tion of MCP mutation allows the withdrawal of plas-
matherapy. For patients with CFH, CFI, C3 or CFB
mutations, modality (PE or PI) and interval of time
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matherapy should probably never be stopped in patients
with a CFH mutation, maybe also a CFI mutation com-
bined with another complement anomaly, or a C3 or CFB
mutation. However, an attempt to withdraw plasmather-
apy is generally considered in patients who do not present
any manifestation of HUS despite tapering PE/PI to
monthly or less than monthly administration since several
months or years. In case of infection, biological controls
should be performed to detect and treat a potential relapse
early, by intensification of plasmatherapy to daily sessions.
The limits of plasmatherapy
Logistic and technical difficulties may limit the feasibility
of PE over the long term. PE need technically trained
center, especially for children [126,127]. If the patient
has no arteriovenous fistula, a central venous catheter
similar to those used for hemodialysis is necessary, with
the risk of central venous thrombosis, particularly in
young children, and infection. Some patients develop
anaphylactic reactions to FFP, which may require cessa-
tion of any form of plasmatherapy.
Renal transplantation: indications, risks and new issues
The risk of post-transplant recurrence of aHUS according to
complement abnormality
Any aHUS patient who has reached ESRF is theoretically a
candidate to renal transplantation. However, the overall
risk of aHUS recurrence after renal transplantation is 50%
and the risk of graft loss 80-90% in patients with recur-
rence [18,128-131] (Table 3). A high risk of graft failure
due to arterial thrombosis has also been reported in chil-
dren [17]. The risk of post-transplant aHUS recurrence is
75-90% in patients with CFH mutation, 45-80% in patients
with CFI mutation, 40-70% in patients with C3 mutation
[83,131]. The 3 patients with CFB mutations [80,81] and
one with THBD mutation [45] who were transplanted all
lost the graft to recurrence. On the opposite, the risk of
recurrence is low (from zero [18] to 15-20% [131] in
patients with MCP mutation, a logic issue as the graft
brings the non-mutated MCP protein. The variability of
the risk of post-transplant recurrence for instance in the
CFI, C3 and MCP-mutated groups has to be interpreted
with the present knowledge of a high frequency of asso-
ciated genetic risk factors. As more than half of CFI-muta-
tion carriers have been shown to harbor an additional
susceptibility factor for aHUS, the risk of recurrence in
patients with isolated CFI mutations should be reassessed
[28]. In the same line, the few MCP-mutated patients
reported with post-transplant recurrence could have had
uninvestigated associated complement abnormalities
responsible for the recurrence.
Post-transplant recurrence generally occurs very early
in patients with CFH mutation: during the first days or
the first month in half of reported cases, between the
second and the sixth month in the other cases (data
issued from references in [129]). However, some patients
have recurrence only after several years. The delay until
recurrence seems more variable in patients with CFI
mutation, either during the first days post-transplant or
after several months or years [129,132]. Recurrence
sometimes does not present as a full-blown HUS, but as
heavy proteinuria and a progressive deterioration of the
graft function without hemolysis and thrombocytopenia,
with TMA lesions at graft biopsy. In the majority of
cases, untreated recurrence ends-up in graft loss, typically
within the first year of transplantation.
The risk of post-transplant recurrence in patients with
anti-CFH antibodies is not well documented, but recur-
rence can be expected if a high titer of antibodies persists
at the time of transplantation. A reduction of anti-CFH
antibody levels with plasma exchanges and rituximab
enabled successful transplantation in 2 patients
[37,122,133]. Publications have reported that recurrence-
free transplantation was achievable in patients with anti-
CFH antibody without any specific treatment [71,134].
However, pretransplant screening of anti-CFH antibodies
or determination of their titre was not available in these
observations. The assessment of the risk of post-transplant
recurrence is complicated by the report that patients with
anti-CFH antibodies may also carry mutations in CFH,
CFI, MCP or C3 [71].
There is also a risk of recurrence in patients with no
mutation and no anti-CFH antibodies, although not well
established.
Living-related kidney donation is not recommended
Considering the risk of graft loss to recurrence, living-
related kidney donation must be considered as contra-
indicated for patients with CFH, CFI, CFB, C3 or THBD
mutation, questionable for patients with unexplained
aHUS, debatable for patients with MCP mutation. In
addition, the risk for the donor to develop HUS after
kidney donation has to be taken into account. This has
been reported in four donors who had HUS three
weeks to ten months after donation [129]. CFH muta-
tion was subsequently demonstrated in one of the
donors and his recipient. Considering the incomplete
penetrance of the disease, the role of complement gene
polymorphisms and the genetic variability within mem-
bers of a single family, it is impossible to reach one
hundred percent certitude of “no risk of aHUS” for liv-
ing-related donors.
Prevention/rescue of post-kidney transplant aHUS
recurrence
Bilateral nephrectomy o fn a t i v ek i d n e y si so f t e np e r -
formed before transplantation because of severe hyper-
tension or ongoing hemolysis and thrombocytopenia.
Unfortunately, this does not reduce the risk of aHUS
post-transplant recurrence [17].
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Some studies have suggested that avoidance of calci-
neurin inhibitors, that have an endothelial toxicity,
might be beneficial [135] but others have reported con-
flicting results [128,129,131]. One explanation could be
that calcineurin-free protocoles often rely on sirolimus,
now demonstrated to be toxic to the endothelium and
predisposing to TMA, through its role of VEGF down-
regulation [7-11]. Owing to these problems and the
increased risk of rejection in calcineurin-free regimens,
aHUS is not considered per se as a contraindication to
calcineurin inhibitors [125].
Plasmatherapy to rescue or prevent post- kidney transplant
aHUS recurrence
Many patients of historical series have received some form
of plasmatherapy at the time of recurrence [17,128-131].
As time at plasmatherapy initiation, modalities (PE or PI),
volume of FFP infused or exchanged, frequency and dura-
tion were highly variable, the effect of plasmatherapy is
difficult to ascertain. However, most studies suggest that
plasmatherapy at the time of recurrence often fails to res-
cue kidney function and to prevent graft loss [128-131].
Therefore preventive plasmatherapy is now recommended
[125]. In the line of plasmatherapy recommended for
aHUS on native kidneys, one PE session should be per-
formed just before transplant surgery, FFP infused during
surgery, and PE continued daily for at least 5 days, then 5
sessions per week during 2 weeks, 3 sessions per week
during 2 weeks, subsequently tapered on a case by case
basis according to the evolution (Figure 9). To our knowl-
edge, preventive plasmatherapy has been successful to pre-
vent recurrence in ten renal transplant recipients,
including 5 with CFH mutation [113,131,136-138], 3 with
CFI mutation [131,139], 2 with C3 mutation [121,131].
The efficiency of prophylactic plasmatherapy started
before renal transplantation is particularly demonstrated
in one family [113,137]. Three siblings, including two
identical twins, had aHUS with CFH S1191L mutation,
SCR20. The eldest child lost a first graft for recurrent
HUS. One of the identical twins had preserved function of
her native kidneys under prophylactic PE at 6 years fol-
low-up. The second twin had a successful renal transplan-
tation with PE started just before surgery and maintained
subsequently, with serum creatinine 127 μmol/l at 5 years
post-transplantation. The eldest sister lost a second graft
despite prophylactic PE, when they were decreased from
1/week to 1/two weeks [113]. A third graft was successful
under 2 PE weekly, but the child developed plasma intol-
erance and was switched to eculizumab [137]. Of note,
two other patients, both with a CFH R1210C mutation in
SCR20, received pre, per and postoperative PE/PI for only
2.5 and 3 months respectively and were free of recurrence
at 1 year and 3 years follow-up respectively [136,138].
These observations confirm the benefit of preventive plas-
matherapy started before surgery and maintained inten-
sively during the first months after transplantation. They
also show that subsequent program of plasmatherapy can
only be empirical.
Combined liver-kidney transplantation to cure aHUS
As CFH, CFI, CFB and C3 are synthesized in the liver,
liver or combined liver-kidney transplantation was logi-
cally proposed. To our knowledge, there have been 20
such transplants (19 for CFH mutation, 1 for CFB muta-
tion) [51,125,140-147] (10 unpublished cases). Most (18)
of the patients were in ESRF and received combined
liver-kidney transplantation. The initial experience in 3
children with CFH mutation was disappointing, as 2
patients had primary hepatic non-function, with exten-
sive microvascular thrombosis and complement deposi-
tion [140,141]. One of them recovered after a second
liver transplantation and had no symptoms of HUS for 3
years, showing that liver transplantation did cure HUS,
but ultimately died from the neurologic sequel of the
hepatic encephalopathy [125,140]. The other child died
in the early post-transplant period [141]. The third child
had no symptoms of HUS during nearly one year after
isolated liver transplantation, again confirming the effi-
ciency of the procedure, but died from post-transplant
lymphoproliferative disease [142]. The first 2 observa-
tions suggested that it was necessary to provide a large
amount of CFH just before liver reperfusion, to obviate
the massive complement activation associated with reper-
fusion and its thrombogenic consequences. Therefore,
four subsequent combined liver-kidney transplantations,
also in children with CFH mutation, were performed
with intensive pre-operative plasmatherapy (PE with FFP
50-100 ml/kg just before surgery, FFP infusion (20-35
ml/kg during surgery or PE between liver and kidney
Before surgery
PE with FFP  (60-75 ml/kg) within 4-6 h
before graft reperfusion
If hemodialysis, PE after dialysis
During surgery FFP ≥ 10-20 ml/kg
After surgery
PE with FFP  (60-75 ml/kg) 
daily ≥ 5 days
5 / week x 2 weeks
3 / week x 2 weeks
then tapered on a case by case basis
Figure 9 Recommendations for plasmatherapy to prevent
post- kidney transplant recurrence of hemolytic uremic
syndrome, according to the Consensus Study Group [125]. Of
note, preventive eculizumab (started before transplantation) now
has to be considered for patients at very high risk of recurrence. PE,
plasma exchange; FFP, fresh frozen plasma.
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gulation. Both grafts had normal function at follow-up
now largely over one year, and HUS was cured [143-145].
Following this positive experience, recommendations for
intensive pre and per operative plasmatherapy to obviate
complement activation during liver reperfusion were
published [125]. Of the 14 combined transplantations
performed with preconditioning PE and plasma infusions,
12 have been successful. However, 2 children died from
operative vascular difficulties( h e p a t i ca r t e r yt h r o m b o s i s
in one, cerebral ischemia related to superior vena cava
syndrome during manipulation of the inferior vena cava
in the other) [personal communication from J.Saland,
with permission], indicating a 14% operative death rate in
patients receiving combined liver-kidney transplantation
under plasma therapy. Therefore, the decision of com-
bined transplantation to cure the disease needs a precise
appreciation of the risks/benefits on an individual basis.
Complement inhibitors: the new treatment in 2010-2011
Eculizumab
The activation of C5 is essential for the development of
aHUS [55,148]. Eculizumab (Soliris
®, Alexion Pharmaceu-
ticals, Cheshire, CT, USA) is a recombinant, humanized,
monoclonal immunoglobulin G antibody that targets C5.
Eculizumab blocks the cleavage of C5 to C5b, ultimately
preventing the generation of the proinflammatory peptide
C5b and the cytotoxic membrane attack complex C5b-9
(Figure 10).
Eculizumab is approved worldwide for the treatment
of paroxysmal nocturnal hemoglobinuria (PNH) and its
efficacy and good tolerance has been demonstrated in
s e v e r a lh u n d r e d so fp a t i e n t sw i t ht h i sd i s e a s e ,s o m eo f
them treated since up to 10 years [149-151]. Eculizumab
has been granted Orphan Medicinal Product Designa-
tion for the treatment of aHUS by the U.S. Food and
Drug Administration in May 2009 and the European
Medicines Agency in August 2009. This new treatment
has been the object of eager expectations from patients
and physicians during recent years [115,152,153]. 2009
and 2010 have seen the first treatments of aHUS
patients with eculizumab.
Blockade of the complement terminal pathway induces
an increased risk of Neisseria meningitis infection [154].
Therefore patients must receive vaccination against Neis-
seria meningitis before being treated with eculizumab.
However, as no vaccine presently protects against the B
serotype, patients and physicians have to be aware of
symptoms that would necessitate urgent investigations
and antibiotherapy. Some countries (such as France)
require permanent antibioprophylaxis during eculizumab
treatment in addition to vaccination.
Eculizumab binds specifically
to C5 and blocks its cleavage to 
C5a and C5b
Complement proximal    functions 
are preserved :
- opsonization of micro-organisms
- clearance of  immune complexes
Terminal complement activation   is inhibited
Æ increased susceptibility to meningococcal infections
Figure 10 Blockade of terminal complement activation, adapted from [149]. Eculizumab binds to C5 and prevents the formation of the
membrane attack complex by reducing cleavage of C5 to C5a and C5b.
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than for PNH, in order to completely block the comple-
ment terminal activation. Schedule of administration is
the same as for PNH: in adults, 900 mg (intravenous over
30 minutes), weekly for 4 weeks (a total of 4 injections at
weekly interval), then 1200 mg for the fifth injection and
then every 14 days as maintenance treatment on the long
term. These doses induce eculizumab circulating trough
levels > 35 μg/mL that consistently block terminal com-
plement activation. Doses for children are adapted to
weight. As experience with eculizumab is limited in chil-
dren, control of the pharmacokinetics and pharmacody-
namics of the drug and the degree of complement
blockade (CH50 < 10% expected) will be important in
this age group.
Clinical experience with eculizumab in aHUS
At present, 17 patients have been published and reported
in congresses (abstracts available on the net) who
received eculizumab either for aHUS on their native kid-
neys (Table 9) [155-161] or to rescue [121,131,137,
162-166] or prevent [167-169] post-transplant recurrence
(Table 10). Of the 17 patients, 8 were children (aged
from 19 months to 18 years) and 6 had CFH mutation, 2
had C3 mutation, 1 had CFI mutation, 4 had no mutation
identified and genetic was not documented in 2. In the
7 patients treated for aHUS on their native kidneys
(Table 9), improvement in platelet count, cessation of
hemolysis and improvement of kidney function strikingly
occurred within a few days after eculizumab initiation.
All five patients maintained on long term eculizumab
had preserved renal function at follow-up from 10 weeks
to 2 years 4 months. Two patients who received a single
dose of eculizumab went to ESRF after a relapse of HUS
1 month [157] and 2 months [158] after eculizumab ces-
sation. In addition, one of them was treated late in the
course of the disease, after approximately fifty days on
dialysis [157]. Of the 10 patients treated to prevent or
rescue post-transplant recurrence, 6 had lost one or two
previous grafts because of recurrence (Table 10). Remis-
sion of HUS was obtained within a few days and the three
patients treated prophylactically did not experience recur-
rence. All 8 patients maintained on long term eculizumab
treatment had preserved graft function and remission of
HUS at follow up from 4 months to 2 years 5 months.
T w op a t i e n t sw h or e c e i v e das i n g l ed o s eh a ds u b s e q u e n t
relapse after 11 and 21 months and ultimately lost the
graft [162,165].
International multicenter prospective phase II trials
have been conducted in 2009-2010 in adults and adoles-
cents (≥ 12 years) with aHUS (primary disease or post-
transplant recurrence), either plasma resistant (17
patients) or plasma sensitive (on chronic plasmatherapy)
(20 patients), who were switched from plasmatherapy to
eculizumab [170,171]. These trials confirmed that
eculizumab inhibits the TMA process in aHUS patients,
with reversal of thrombocytopenia and hemolysis and
improvement of renal function, whether they were unre-
sponsive to plasmatherapy or on chronic plasmatherapy
before receiving eculizumab. Response to eculizumab
was achieved with the first dose of eculizumab and
improvement of renal function continued with sustained
therapy. In both groups, no patient required TMA inter-
vention (plasmatherapy or new dialysis) while on eculi-
zumab. Eculizumab was well tolerated. This beneficial
response was observed both in patients with or without
identified complement mutation. A prospective trial in
children aged from 1 month to 18 years and a new trial
in adults have started at the end of 2010, including
patients with primary HUS or post-transplant recur-
rence, whether receiving plasmatherapy or not [172].
Overall, these results demonstrate the potential for
eculizumab treatment as the new standard of care for
patients with aHUS. 2011 probably is a transition year.
Many physicians, especially pediatricians because of the
difficulty of PE in young children, consider that eculizu-
mab can now be administered without previous plas-
matherapy. Whatever the patient’sa g e ,r e s i s t a n c eo r
incomplete response to plasmatherapy (defined by persis-
tant thrombocytopenia and/or hemolytic anemia and/or
the absence of improvement of renal function after 3 to 5
daily PE), occurrence of a relapse at plasmatherapy taper-
ing or cessation, intolerance to plasma or vascular access
difficulties are or will be indications to replace plas-
matherapy by eculizumab when available and refunded.
This new therapeutic option also changes the strategy
for kidney transplantation. Transplantation physicians
now have to consider they should treat the patient with
eculizumab in case of HUS recurrence despite preventive
plasmatherapy. If the risk of recurrence is extremely high
(previous graft lost to recurrence in the patient, a family
member or a patient with the same mutation from series
and registries), the logic of preventive eculizumab to pre-
vent recurrence is hardly questionnable. Finally, the indi-
cations of combined kidney-liver transplantation -under
plasmatherapy or eculizumab to block complement activa-
tion at liver reperfusion-today appear limited, although
this possibility to cure the disease must not be discarded.
New therapies for the near future
Other complement blockers which block the comple-
ment activation at the endothelium surface without
blocking it in the fluid phase will become available in the
near future [173]. A human plasma-derived CFH concen-
trate, developed by the Laboratoire Français du Fraction-
nement et des Biotechnologies, received the European
Orphan Drug designation in January 2007 and ought to
be available for clinical trials in the near future. This
CFH concentrate has been shown in Cfh-gene knockout
mice -which develop plasma C3 deficiency and massive
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Reference Mutation Age at onset of HUS,
evolution and
response to
plasmatherapy
Age at
eculizumab
initiation
Response to
plasmatherapy of HUS
episode at eculizumab
initiation
Serum
creatinine level
at eculizumab
initiation
Delay of hematological
and renal improvement
after initiation of
eculizumab
Delay until complete
remission of HUS after
initiation of eculizumab
Protocol Evolution of
HUS
Last Screat
(follow-up
under
eculizumab)
Gruppo et
al
2009 [155]
R. Gruppo
PC
NI < 8 days
3 relapses over 11 m,
PI sensitive
19 m PE resistant 265 μmol/L 2 days 10 days Complete
protocol
Remission
35 μmol/L
(2 y 4 m)
Fremont et
al
2009 [156]
CFH 4 y 4 y PE partially sensitive 80 μmol/L ND 2 weeks Complete
protocol
Remission
26 μmol/L
(10 weeks)
Mache et al
2009 [157]
NI 17.8 y
PE sensitive
3 relapses at PE
tapering
17.11 y PE resistant 690 μmol/L ~ 3 days
(platelets increase)
5 days (hematologic
remission)
Single
dose
Relapse at 2w
ESRF
Kose et al
2010 [158]
NI 18 y 18 y PE resistant ~310 μmol/L 1 day ~ 7 days Single
dose Relapse at 2m
ESRF
Lapeyraque
et al 2010
[159]
AL.
Lapeyraque
PC
CFH
S1191L
V1197A
7m
11 relapses over 5.4 y,
PE/PI sensitive
6 y PI resistant 108 μmol/L A few days 1 week Complete
protocol
Remission
44 μmol/L
(1 y 3 m)
Prescott et
al
2010 [160]
HC. Prescott
PC
CFI
p.A258T
47 y
PE sensitive
Relapse 2 w after PE
cessation
47 y PE resistant 610 μmol/L - 7 days (Screat decrease)
- 49 days
(platelets normalization)
~1.5 m Complete
protocol
Remission
230 μmol/L
(7 m)
Ohanian et
al 2011
[161]
ND 50 y 50 y No plasmatherapy 600 μmol/L - 4 days (LDH decrease)
- 10 days (Screat decrease)
~ 1.5 m Complete
protocol
Remission
198 μmol/L
(2.5 m)
PC: personal communication, with permission; Screat: serum creatinine; CFH: factor H; CFI: factor I; NI: none identified; ND: not documented; ESRF: end stage renal failure; PE: plasma exchange; PI: plasma infusion
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0Table 10 Case reports of patients with post-transplant recurrence of atypical hemolytic uremic syndrome treated with eculizumab
Reference Gene Previous
transplantations
Age and post-tx
course before
eculizumab initiation
Delay from
recurrence to
eculizumab
initiation
Screat at
eculizumab
initiation
μmol/L
Delay until platelet increase/
hemolysis resolution/Screat
decrease under eculizumab
Protocol Recurrence
after
eculizumab
cessation
(delay)
Evolution under
eculizumab
Last Screat
(follow-up under
eculizumab)
Nurnberger
2009 [162]
J.
Nurnberger
PC
CFH
Y475S
1st tx:
recurrence at 5 w, PE
resistant, graft loss
37 y, 2
nd tx
Recurrence
at 6 w
PE resistant
5 days 132 2 days/6 days/24 h Single
dose
Likely but not
biopsy proven
(21 m).
Graft loss.
/
Chatelet
2009 [121]
2010 [163]
V.Chatelet
PC
C3
R570Q
1st tx:
recurrence at 5 m,
graft loss after 2 y
43 y, 2
nd tx
Recurrence
at 3 y
PE sensitive/dependent
14 m 320 A few days/a few days/~1 month Complete
protocol
NA 2 recurrences of
hemolytic anemia
when injections
delayed by 6-8 days
230 μmol/L
(2 y 5 m)
Legault
2009 [164]
ND No 34 y, 1
st tx
Recurrence at 1 m and
5 m, PE sensitive
initially, then resistant
9 m 323 ND/ND/4 weeks Complete
protocol
NA Remission
238 μmol/L
(6 m)
Davin
2010 [137]
JC. Davin
PC
CFH
S1191L
1
st tx: recurrence at
day 3, graft loss
2
nd tx under
prophylactic PE:
recurrence at 10 w,
graft loss
17 y, 3
rd tx Preventive
PE
Recurrence at
4 m, rescue
(PE intensification)
Plasma intolerance at
10 m
10 m 131 NA (in remission at eculizumab
initiation)
Complete
protocol
NA Remission
130 μmol/L
(1 y 10 m)
Larrea
2010 [165]
M.Lozano
PC
NI No 22 y, 1
st tx
Recurrence at day 12
PE resistant
9 days 415 36 h/36 h/3 days Single
dose
Yes (11.5 m)
Eculizumab
resumed
Remission
177 μmol/L
(5 m)
Graft loss after 2
nd
eculizumab cessation
(humoral rejection)
Zuber
2010 [131]
J. Zuber
PC
CFH 1
st tx: recurrence, graft
loss
24 y, 2
nd tx Preventive
PI/PE
Recurrence at day 1
PE resistant
4 days 500 24 h/24 h/3 days Complete
protocol
NA Remission
62 μmol/L
(9 m)
Al-Akash
2010 [166]
SI. Al-Akash
PC
C3
R570W
1
st tx: recurrence at 4
y, graft loss
2
nd tx: recurrence at 2
m, graft loss
15 y, 3
rd tx Preventive
PE
Recurrence at 2 m, PE
partially sensitive
~20 days 220 A few days Complete
protocol
NA Remission
115 μmol/L
(1 y 5 m)
Zimmerhakl
2010 [167]
M.Riedl
PC
CFH
W1183C
No 10 y, 1
st tx Preventive
PE
Preventive
eculizumab
~ 45 NA Complete
protocol
NA No recurrence
44 μmol/L
(2 y 1 m)
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Weitz
2011 [168]
CFH
E1198
stop
No 7 y, 1
st tx Preventive
eculizumab
NA
(dialysis)
NA Complete
protocol
NA No recurrence
Normal Screat
(7 m)
Nester
2011 [169]
Hybrid
CFH
No 12 y, 1
st tx
Preventive PE
Preventive
eculizumab
NA
(dialysis)
NA Complete
protocol
NA No recurrence
80 μmol/L
(4 m)
Preventive: started before transplantation or before recurrence; PC: personal communication, with permission; Screatinine: serum creatinine; CFH: factor H; NI: none identified; Tx: transplantation; NI: none identified;
ND: not documented; NA: not applicable; PE: plasma exchange
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membrane-to result in rapid normalization of plasma C3
levels and resolution of the glomerular basement mem-
brane C3 deposits [174]. Recombinant CFH might also
become available in the future [175,176].
Outcome
Data on outcome and prognosis rely mostly on historical
series, including patients who received either no plas-
matherapy or plasmatherapy modalities which would
now be considered as inadequate (started too late, not
aggressive enough (PI instead of PE), stopped too early).
However these series illustrate the natural outcome of
the disease or the best evolution possibly obtained with
the plasmatherapy modalities commonly achieved and/or
feasible.
Among the French pediatric cohort, mortality during the
acute phase of HUS was 8.6% and 24% of survivors devel-
oped end stage renal disease (ESRD) at first episode [17].
In the Italian cohort, mortality at first episode was 8,4%,
ranging from 12% in children to 2% in adults, and 32% of
survivors did not recover renal function at first episode
[18]. Relapses of HUS are mostly observed in patients with
mutations of MCP (70%-90% of patients have relapses)
[17,18], CFH (50%) [17,18], C3 (50%) [18,83,84] and anti-
CFH antibodies (40-60%) [18,37]. In MCP-mutated
patients, relapses occur at unpredictable intervals of a few
months to several years, most often triggered by infections.
Relapses with complete recovery are characteristic of
MCP-HUS in children [17,18] (Table 3).
aHUS patients have been noticed to have cardiovascu-
lar ischemic events complicating flares of the disease
[18,41]. Stenoses of intra-and extracranial arteries, large
thoracic and abdominal aorta branches, pulmonary and
coronary arteries have been demonstrated in a 10 year-
old child with aHUS and a CFB mutation [177] and cer-
ebral artery stenoses in a 15 year-old child with CFH
mutation [178]. These observations suggest that aHUS
with complement dysregulation may involve large
arteries and support the logic of complement inhibition
by anti-C5 antibody.
Prognosis
The data presented here come from the two main cohorts
of clinically documented patients: the French pediatric
cohort [17] and the Italian cohort concerning children and
adults [18], which included both retrospective and recent
patients, but none treated by eculizumab. The overall mid-
term prognosis of aHUS was poor, and more severe in
adults than in children. At 3 to 5 years after onset, 44%
[17] to 48% [18] of children and 67% of adults [18] had
either died or reached ESRF.
Prognosis varies according to genotype (Table 3). The
worst prognosis is in patients with CFH mutation and
the best in patients with MCP mutation. In CFH-mutated
patients, mortality at first episode was 20-30% in children
(a percentage now historical) and 4% in adults and evolu-
tion to ESRF at first episode in survivors 20-40% in chil-
dren and 48% in adults [17,18]. By comparison, no
patient with MCP mutation from either cohort died at
first episode, none of the MCP-children and only 25% of
MCP-adults developed ESRF at first episode. Among
patients with CFI mutations, 50-60% went to ESRF at
first episode or within the year after onset, while the
other half have preserved renal function generally with-
out further relapses [17,18]. At three to five years follow-
up, the percentage of patients who had died or reached
ESRF was approximately 75% in CFH-mutated patients
and 50-60%% in CFI-mutated patients, whether adults or
children [17,18]. While 38% of MCP-mutated children in
the French pediatric cohort had reached ESRF at 5 years
follow-up after a number of relapses, only 6% of MCP-
mutated patients in the Italian registry had developed
ESRF at that stage, varying from 0% in children to 25% in
adults [18]. The prognosis of HUS with C3 [18,83] or
CFB [18,80,81] mutation is as poor as that of CFH-HUS,
whatever the age at onset. Patients with THBD mutations
also have a poor outcome, with evolution to ESRD in
46% of patients at 1 year and 54% at 3 years follow-up
[18]. Among patients with anti-CFH antibodies, 35% [37]
to 60% [18] developed ESRD within 3 years follow-up.
Recent progress in diagnosis (e.g. early detection of
anti-CFH antibodies) and therapeutic options, including
early aggressive and prolonged plasma therapy and the
use of eculizumab, most probably will allow a much bet-
ter outcome of the disease. It is not unrealistic to con-
sider that the poor prognosis indicated by presently
available cohorts will soon appear as outdated.
Conclusion
The progress in the understanding of the physiopathol-
ogy of aHUS during the last decade has opened the way
to new therapies which hopefully will prevent the evolu-
tion to ESRF in the patients at risk, and allow a successful
transplantation in the patients presently on dialysis.
Recent trials and clinical experience confirm the effi-
ciency of the complement blocker eculizumab. The chal-
lenge is now to define the best choice for each individual
patient, according to the identified complement anomaly
(ies) and the phase of the disease, between plasma ther-
apy, eculizumab, liver or combined live-kidney transplan-
tation and, in the near future, CFH concentrate or
recombinant CFH. Thanks to the progress in knowledge
and comprehension, the disease has entered a new era.
Abbreviations
ADAMTS 13: A Disintegrin And Metalloprotease with ThromboSpondin type
1 repeats 13; aHUS: atypical hemolytic uremic syndrome; APL:
Loirat and Frémeaux-Bacchi Orphanet Journal of Rare Diseases 2011, 6:60
http://www.ojrd.com/content/6/1/60
Page 24 of 30antiphospholipid; CFH: complement factor H; CFI: complement factor I; CFB:
complement factor B; CNS: central nervous system; D+ HUS: post-diarrheal
hemolytic uremic syndrome; (D-) HUS: non-post-diarrheal hemolytic uremic
syndrome; Elisa, enzyme linked immunosorbent assay; ESRF: end-stage renal
failure; FFP: fresh frozen plasma; HELLP syndrome: Hemolytic anemia,
elevated Liver enzymes, and Low Platelets syndrome; HLA: human leukocyte
antigen; HUS: hemolytic uremic syndrome; LDH: lactate deshydrogenase;
MAC: membrane attack complex; MCP: membrane cofactor protein; MLPA:
Multiplex Ligation dependent Probe Amplification; MRI: magnetic resonance
imaging; PCR: polymerase chain reaction; PI: plasma infusion; PE: plasma
exchange; RBC: red blood cell; RCA: regulators of complement activation;
SCR: short consensus repeat; SLE: systemic lupus erythematosus; SNP: Single
Nucleotide Polymorphism; Stx: Shiga-like toxin; STEC: Shiga-toxin producing
Escherichia coli; S pneumoniae: Streptococcus pneumoniae; THBD:
thrombomodulin; TMA: thrombotic microangiopathy; TTP: thrombotic
thrombocytopenic purpura; USA: United States of America; VEGF: vascular
endothelial growth factor
Acknowledgements
Dr Fadi Fakhouri, Dr Julien Zuber and the Groupe d’Etude du SHU et des
Glomérulonéphrites membranoprolifératives for stimulating discussions; the
Association pour l’Information et la Recherche sur les maladies rénales
Génétiques (AIRG) for financial support and the help and encouragement
offered to patients, families, physicians and staffs of nephrology
departments; the patients and their families for their collaboration and
support.
Author details
1Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré; Université
Paris VII; Pediatric Nephrology Department; Paris, France.
2Assistance
Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou; Biological
Immunology Department; Paris, France.
Authors’ contributions
CL and VFB discussed the article’s content, wrote the manuscript, reviewed
it before submission and approved the final manuscript. VFB carried out
complement investigations and genetic screening.
Competing interests
C. Loirat has been coordinator for France of the Alexion trials “Safety and
efficacy of Eculizumab in atypical HUS adult patients resistant to plasma
therapy/sensitive to plasmatherapy” C08-002A and C08-003A, is coordinator
for France of the trials “Eculizumab in adult patients/pediatric patients with
atypical HUS” C10-004 and C10-003, and is on scientific advisory boards of
Alexion Pharmaceuticals and LFB Biotechnologies. V. Frémeaux-Bacchi is on
scientific advisory board of Alexion Pharmaceuticals.
Received: 7 December 2009 Accepted: 8 September 2011
Published: 8 September 2011
References
1. Besbas N, Karpman D, Landau D, Loirat C, Proesmans W, Remuzzi G,
Rizzoni G, Taylor CM, Van de Kar N, Zimmerhackl LB: A classification of
hemolytic uremic syndrome and thrombotic thrombocytopenic purpura
and related disorders. Kidney Int 2006, 70:423-431.
2. Noris M, Remuzzi G: Hemolytic uremic syndrome. J Am Soc Nephrol 2005,
16:1035-1050.
3. Johnson S, Taylor CM: What’s new in haemolytic uraemic syndrome? Eur
J Pediatr 2008, 167:965-971.
4. Scheiring J, Rosales A, Zimmerhackl LB: Clinical practice. Today’s
understanding of the haemolytic uraemic syndrome. Eur J Pediatr 2010,
169:7-13.
5. Keir L, Coward RJ: Advances in our understanding of the pathogenesis
of glomerular thrombotic microangiopathy. Pediatr Nephrol 2011,
26:523-533.
6. Allen U, Licht C: Pandemic H1N1 influenza A infection and (atypical)
HUS–more than just another trigger? Pediatr Nephrol 2011, 26:3-5.
7. Sartelet H, Toupance O, Lorenzato M, Fadel F, Noel LH, Lagonotte E,
Birembaut P, Chanard J, Rieu P: Sirolimus-induced thrombotic
microangiopathy is associated with decreased expression of vascular
endothelial growth factor in kidneys. J Transplant 2005, 5:2441-2447.
8. Rodriguez R, Nakamura R, Palmer JM, Parker P, Shayani S, Nademanee A,
Snyder D, Pullarkat V, Kogut N, Rosenthal J, Smith E, Karanes C,
O’Donnell M, Krishnan AY, Senitzer D, Forman SJ: A phase II pilot study of
tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic
stem cell transplantation using 3 conditioning regimens. Blood 2010,
115:1098-1105.
9. Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G: Angiogenesis
inhibitor therapies: focus on kidney toxicity and hypertension. Am J
Kidney Dis 2007, 5:203-218.
10. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J,
Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L,
Alpers CE, Quaggin SE: VEGF inhibition and renal thrombotic
microangiopathy. N Engl J Med 2008, 358:1129-1136.
11. Bollée G, Patey N, Cazajous G, Robert C, Goujon JM, Fakhouri F, Bruneval P,
Noël LH, Knebelmann B: Thrombotic microangiopathy secondary to VEGF
pathway inhibition by sunitinib. Nephrol Dial Transplant 2009, 24:682-685.
12. Sharma AP, Greenberg CR, Prasad AN, Prasad C: Hemolytic uremic
syndrome (HUS) secondary to cobalamin C (cblC) disorder. Pediatr
Nephrol 200, 22:2097-2103.
13. Van Hove JL, Van Damme-Lombaerts R, Grünewald S, Peters H, Van
Damme B, Fryns JP, Arnout J, Wevers R, Baumgartner ER, Fowler B:
Cobalamin disorder Cbl-C presenting with late-onset thrombotic
microangiopathy. Am J Med Genet 2002, 111:195-201.
14. Adams D, Venditti CP: Disorders of Intracellular Cobalamin Metabolism.
Edited by: Pagon RA, Bird TC, Dolan CR, Stephens K. GeneReviews [Internet].
Seattle (WA): University of Washington, Seattle 1993; 2008:, [updated 2009
Aug 11].
15. Kaplan BS, Chesney RW, Drummond KN: Hemolytic uremic syndrome in
families. N Engl J Med 1975, 292:1090-1093.
16. Fakhouri F, Fremeaux-Bacchi V: Does hemolytic uremic syndrome differ
from thrombotic thrombocytopenic purpura? Nat Clin Pract Nephrol 2007,
3:679-687.
17. Sellier-Leclerc AL, Fremeaux-Bacchi V, Macher MA, Niaudet P, Guest G,
Boudailliez B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fishbach M,
Morin D, Nivet H, Alberti C, Loirat C: Differential impact of complement
mutations on clinical characteristics in atypical hemolytic uremic
syndrome. J Am Soc Nephrol 2007, 18:2392-2400.
18. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E,
Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der
Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G: Relative role of
genetic complement abnormalities in sporadic and familial aHUS and
their impact on clinical phenotype. Clin J Am Soc Nephrol 2010,
5:1844-1859.
19. Constantinescu AR, Bitzan M, Weiss LS, Christen E, Kaplan BS, Cnaan A,
Trachtman H: Non-enteropathic hemolytic uremic syndrome: causes and
short-term course. Am J Kidney Dis 2004, 43:976-982.
20. Sullivan M, Erlic Z, Hoffmann MM, Arbeiter K, Patzer L, Budde K, Hoppe B,
Zeier M, Lhotta K, Rybicki LA, Bock A, Berisha G, Neumann HP:
Epidemiological approach to identifying genetic predispositions for
atypical hemolytic uremic syndrome. Ann Hum Genet 2010, 74:17-26.
21. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelleti F, Bettinaglio P, Mele C,
Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G,
Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G: Genetics of
HUS: the impact of MCP, CFH and IF mutations on clinical presentation,
response to treatment, and outcome. Blood 2006, 108:1267-1279.
22. Westra D, Volokhina E, van der Heijden E, Vos A, Huigen M, Jansen J, van
Kaauwen E, van der Velden T, van de Kar N, van den Heuvel L: Genetic
disorders in complement (regulating) genes in patients with atypical
haemolytic uraemic syndrome (aHUS). Nephrol Dial Transplant 2010,
25:2195-2202.
23. Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJ: Mutations in
alternative pathway complement proteins in American patients with
atypical hemolytic uremic syndrome. Hum Mutat 2010, 31:E1445-1460.
24. Coppo P, Schwarzinger M, Buffet M, Wynckel A, Clabault K, Presne C,
Poullin P, Malot S, Vanhille P, Azoulay E, Galicier L, Lemiale V, Mira JP,
Ridel C, Rondeau E, Pourrat J, Girault S, Bordessoule D, Saheb S,
Ramakers M, Hamidou M, Vernant JP, Guidet B, Wolf M, Veyradier A, French
Reference Center for Thrombotic Microangiopathies: Predictive features of
severe acquired ADAMTS13 deficiency in idiopathic thrombotic
microangiopathies: the French TMA reference center experience. PLoS
One 2010, 5:e10208.
Loirat and Frémeaux-Bacchi Orphanet Journal of Rare Diseases 2011, 6:60
http://www.ojrd.com/content/6/1/60
Page 25 of 3025. Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN: Survival and
relapse in patients with thrombotic thrombocytopenic purpura. Blood
2010, 115:1500-1511.
26. Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, Carreras Berges L, López-
Trascasa M, Sánchez-Corral P, Rodríguez de Córdoba S: Predisposition to
atypical hemolytic uremic syndrome involves the concurrence of
different susceptibility alleles in the regulators of complement activation
gene cluster in 1q32. Hum Mol Genet 2005, 14:703-712.
27. Dragon-Durey MA, Blanc C, Marliot F, Loirat C, Blouin J, Sautes-Fridman C,
Fridman WH, Frémeaux-Bacchi V: The high frequency of Complement
Factor H-Related CFHR1 Gene deletion is restricted to specific
subgroups of patients with atypical Haemolytic Uraemic Syndrome.
J Med Genet 2009, 46:447-450.
28. Bienaimé F, Dragon-Durey M-A, Regnier CH, Nillson SC, Kwan WH, Blouin J,
Jablonski M, Renault N, Rameix-Welti M-A, Loirat C, Sautés-Fridman C,
Villoutreix BO, Blom AM, Fremeaux-Bacchi V: Mutations in components of
complement influences the outcome of Factor Iassociated atypical
hemolytic uremic syndrome. Kidney Int 2009, 77:339-349.
29. Milford DV, Taylor CM, Guttridge B, Hall SM, Rowe B, Kleanthous H:
Haemolytic uraemic syndromes in the British Isles 1985-8: association
with verocytotoxin producing Escherichia coli. Part 1: Clinical and
epidemiological aspects. Arch Dis Child 1990, 65:716-721.
30. Surveillance of post-diarrheal hemolytic uremic syndrome in children
less than 15 years of age in France. Institut de Veille Sanitaire, Ministère
de la Santé, France;[http://www.invs.sante.fr].
31. Loirat C, Noris M, Fremeaux-Bacchi V: Complement and the atypical
hemolytic uremic syndrome. Pediatr Nephrol 2008, 23:1957-1972.
32. Kwon T, Belot A, Ranchin B, Baudouin V, Fremeaux-Bacchi V, Dragon-
Durey MA, Cochat P, Loirat C: Varicella as a trigger of atypical haemolytic
uraemic syndrome associated with complement dysfunction: two cases.
Nephrol Dial Transplant 2009, 24:2752-2754.
33. Bento D, Mapril J, Rocha C, Marchbank KJ, Kavanagh D, Barge D, Strain L,
Goodship TH, Meneses-Oliveira C: Triggering of atypical hemolytic uremic
syndrome by influenza A (H1N1). Ren Fail 2010, 32:753-756.
34. Trachtman H, Sethna C, Epstein R, D’Souza M, Rubin LG, Ginocchio CC:
Atypical hemolytic uremic syndrome associated with H1N1 influenza A
virus infection. Pediatr Nephrol 2011, 26:145-146.
35. Caltik A, Akyüz SG, Erdogan O, Demircin G: Hemolytic uremic syndrome
triggered with a new pandemic virus: influenza A (H1N1). Pediatr Nephrol
2011, 26:147-148.
36. Fang CJ, Fremeaux-Bacchi V, Liszewski MK, Pianetti G, Noris M,
Goodship TH, Atkinson JP: Membrane cofactor protein mutations in
atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3
glomerulonephritis and the HELLP syndrome. Blood 2007, 111:624-632.
37. Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, André JL,
Takagi N, Cheong H, Hari P, Le Quintrec M, Niaudet P, Loirat C,
Fridman WH, Frémeaux-Bacchi V: Clinical features of anti-factor h
autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol
2010, 21:2180-2187.
38. Noris M, Remuzzi G: Atypical hemolytic-uremic syndrome. N Engl J Med
2009, 361:1676-1687.
39. Fakhouri F, Roumenina L, Provot F, Sallée M, Caillard S, Couzi L, Essig M,
Ribes D, Dragon-Durey MA, Bridoux F, Rondeau E, Frémeaux-Bacchi V:
Pregnancy-associated hemolytic uremic syndrome revisited in the era of
complement gene mutations. J Am Soc Nephrol 2010, 21:859867.
40. Koehl B, Boyer O, Biebuyck-Gougé N, Kossorotoff M, Frémeaux-Bacchi V,
Boddaert N, Niaudet P: Neurological involvement in a child with
atypical hemolytic uremic syndrome. Pediatr Nephrol 2010,
25:2539-2542.
41. Sallée M, Daniel L, Piercecchi MD, Jaubert D, Fremeaux-Bacchi V, Berland Y,
Burtey S: Myocardial infarction is a complication of factor H-associated
atypical HUS. Nephrol Dial Transplant 2010, 25:2028-2032.
42. Kaplan BS, Garcia CD, Chesney RW, Segar WE, Giugno K, Chem R:
Peripheral gangrene complicating idiopathic and recessive hemolytic
uremic syndromes. Pediatr Nephrol 2000, 14:985-989.
43. Cameron JS, Vick R: Letter: Plasma-C3 in haemolytic-uraemic syndrome
and thrombotic thrombocytopenic purpura. Lancet 1973, 2:975.
44. Walport MJ: Complement. First of two parts. N Engl J Med 2001,
344:1058-1066.
45. Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-
Favero J, Plaisance S, Claes B, Lambrechts D, Zoja C, Remuzzi G,
Conway EM: Thrombomodulin mutations in atypical Hemolytic-Uremic
Syndrome. N Engl J Med 2009, 361:345-357.
46. Rodrigues de Cordoba SR, de Jorge EG: Translational mini-review series
on complement factor H: genetics and disease associations of human
complement factor H. Clin Exp Immunol 2008, 151:1-13.
47. Kajander T, Lehtinen MJ, Hyvärinen S, Bhattacharjee A, Leung E,
Isenman DE, Meri S, Goldman A, Jokiranta TS: Dual interaction of factor H
with C3d and glycosaminoglycans in host-nonhost discrimination by
complement. Proc Natl Acad Sci USA 2011, 108:2897-2902.
48. Morgan HP, Schmidt CQ, Guariento M, Blaum BS, Gillespie D, Herbert AP,
Kavanagh D, Mertens HD, Svergun DI, Johansson CM, Uhrín D, Barlow PN,
Hannan JP: Structural basis for engagement by complement factor H of
C3b on a self surface. Nat Struct Mol Biol 2011, 18:463-470.
49. Kavanagh D, Richards A, Atkinson J: Complement regulatory genes and
haemolytic uremic syndromes. Annu Rev Med 2008, 59:293-309.
50. Kavanagh D, Goodship T: Genetics and complement in atypical HUS.
Pediatr Nephrol 2010, 25:2431-2442.
51. Sánchez-Corral P, Melgosa M: Advances in understanding the aetiology of
atypical Haemolytic Uraemic Syndrome. Br J Haematol 2010, 150:529-542.
52. Stahl AL, Vaziri-Sani F, Heinen S, Kristoffersson AC, Gydell KH, Raafat R,
Gutierrez A, Beringer O, Zipfel PF, Karpman D: Factor H dysfunction in
patients with atypical hemolytic uremic syndrome contributes to
complement deposition on platelets and their activation. Blood 2008,
111:5307-5315.
53. Licht C, Pluthero FG, Li L, Christensen H, Habbig S, Hoppe B, Geary DF,
Zipfel PF, Kahr WH: Platelet-associated complement factor H in normal
individuals and patients with atypical HUS. Blood 2009, 114:4538-4545.
54. Pickering MC, de Jorge EG, Martinez-Barricarte R, Recalde S, Garcia-Layana A,
Rose KL, Moss J, Walport MJ, Cook HT, de Córdoba SR, Botto M:
Spontaneous hemolytic uremic syndrome triggered by complement
factor H lacking surface recognition domains. J Exp Med 2007,
204:1249-1256.
55. Goicoechea de Jorge E, Paixao-Cavalcante D, Rose KL, Tedesco F, Cook HT,
Botto M, Pickering MC: The development of atypical haemolytic uremic
syndrome depends on complement C5. J Am Soc Nephrol 2011,
22:137-145.
56. Thompson RA, Winterborn MH: Hypocomplementaemia due to a genetic
deficiency of beta 1H globulin. Clin Exp Immunol 1981, 46:110-119.
57. Warwicker P, Goodship TH, Donne RL, Pirson Y, Nicholls A, Ward RM,
Turnpenny P, Goodship JA: Genetic studies into inherited and sporadic
haemolytic uremic syndrome. Kidney Int 1998, 53:836-844.
58. Saunders RE, Abarrategui-Garrido C, Fremeaux-Bacchi V, Goicoechea de
Jorge E, Goodship TH, López Trascasa M, Noris M, Ponce Castro IM,
Remuzzi G, Rodríguez de Córdoba S, Sánchez-Corral P, Skerka C, Zipfel PF,
Perkins SJ, et al: The interactive Factor H-atypical hemolytic uremic
syndrome mutation database and website: update and integration of
membrane cofactor protein and Factor I mutations with structural
models. Hum Mutat 2007, 28:222-234.
59. Ferreira VP, Herbert AP, Cortes C, McKee KA, Blaum BS, Esswein ST, Uhrin D,
Barlow PN, Pangburn MK, Kavanagh D: The binding of factor H to a
complex physiological polyanions and C3b on cells is impaired in
atypical hemolytic uremic syndrome. J Immunol 2009, 182:70097018.
60. Lehtinen MJ, Rops AL, Isenman DE, van der Vlag J, Jokiranta TS: Mutations
in factor H impair regulation of surface-bound C3b by three
mechanisms in atypical hemolytic uremic syndrome. Biol Chem 2009,
284:15650-15658.
61. Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-
Fridman C, Fremeaux-Bacchi V: Alternative complement pathway
assessment in patients with atypical HUS. J Immunol Methods 2011,
365:8-26.
62. Heinen S, Sanchez-Corral P, Jackson MS, Strain L, Goodship JA, Kemp EJ,
Skerka C, Jokiranta TS, Meyers K, Wagner E, Robitaille P, Esparza-Gordillo J,
Rodriguez de Cordoba S, Zipfel PF, Goodship TH: De novo gene
conversion in the RCA gene cluster (1q32) causes mutations in
complement factor H associated with atypical hemolytic uremic
syndrome. Hum Mutat 2006, 27:292-293.
63. Venables JP, Strain L, Routledge D, Bourn D, Powell HM, Warwicker P, Diaz-
Torres ML, Sampson A, Mead P, Webb M, Pirson Y, Jackson MS, Hughes A,
Wood KM, Goodship JA, Goodship TH: Atypical haemolytic uraemic
syndrome associated with a hybrid complement gene. PLoS Med 2006, 3:
e431.
Loirat and Frémeaux-Bacchi Orphanet Journal of Rare Diseases 2011, 6:60
http://www.ojrd.com/content/6/1/60
Page 26 of 3064. Neumann HP, Salzmann M, Bohnert-Iwan B, Mannuelian T, Skerka C, Lenk D,
Bender BU, Cybulla M, Riegler P, Königsrainer A, Neyer U, Bock A,
Widmer U, Male DA, Franke G, Zipfel PF: Haemolytic uraemic syndrome
and mutations of the factor H gene: a registry-based study of German
speaking countries. J Med Genet 2003, 40:676-681.
65. Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H,
Weiss L, Fridman WH, Fremeaux-Bacchi V: Anti-Factor H autoantibodies
associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol
2005, 16:555-563.
66. Józsi M, Strobel S, Dahse HM, Liu WS, Hoyer PF, Oppermann M, Skerka C,
Zipfel PF: Anti factor H autoantibodies block C-terminal recognition
function of factor H in hemolytic uremic syndrome. Blood 2007,
110:1516-1518.
67. Skerka C, Jozsi M, Zipfel PF, Dragon-Durey MA, Fremeaux-Bacchi V:
Autoantibodies in haemolytic uraemic syndrome (HUS). Thromb Haemost
2009, 101:227-232.
68. Strobel S, Hoyer PF, Mache CJ, Sulyok E, Liu WS, Richter H, Oppermann M,
Zipfel PF, Józsi M: Functional analyses indicate a pathogenic role of
factor H autoantibodies in atypical haemolytic uraemic syndrome.
Nephrol Dial Transplant 2010, 25:136-144.
69. Zipfel PF, Edey M, Heinen S, Józsi M, Richter H, Misselwitz J, Hoppe B,
Routledge D, Strain L, Hughes AE, Goodship JA, Licht C, Goodship TH,
Skerka C: Deletion of Complement Factor Hrelated genes CFHR1 and
CFHR3 is associated with atypical haemolytic uremic syndrome. PLoS
Genetics 2007, 3:e41.
70. Józsi M, Licht C, Strobel S, Zipfel SL, Richter H, Heinen S, Zipfel PF, Skerka C:
Factor H autoantibodies in atypical hemolytic uremic syndrome
correlate with CFHR1/CFHR3 deficiency. Blood 2008, 111:1512-1514.
71. Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP,
Schmidt CQ, Staniforth SJ, Holmes LV, Ward R, Morgan L, Goodship TH,
Marchbank KJ: Association of factor H autoantibodies with deletions of
CFHR1, CFHR3, CFHR4 and with mutations in CFH, CFI, CD46, and C3 in
patients with atypical haemolytic uraemic syndrome. Blood 2010,
115:379387.
72. Lee BH, Kwak SH, Shin JI, Lee SH, Choi HJ, Kang HG, Ha IS, Lee JS, Dragon-
Durey MA, Choi Y, Cheong HI: Atypical hemolytic uremic syndrome
associated with complement factor H autoantibodies and CFHR1/CFHR3
deficiency. Pediatr Res 2009, 66:336-340.
73. Richards A, Kemp EJ, Liszewski MK, Goodship JA, Lampe AK, Decorte R,
Müslümanoğlu MH, Kavukcu S, Filler G, Pirson Y, Wen LS, Atkinson JP,
Goodship TH: Mutations in human complement regulator, membrane
cofactor protein (CD46), predispose to development of familial
hemolytic uremic syndrome. Proc Natl Acad Sci USA 2003,
100:12966-12971.
74. Noris M, Brioschi S, Caprioli J, Todeschini M, Bresin E, Porrati F, Gamba S,
Remuzzi G: Familial haemolytic uraemic syndrome and an MCP
mutation. Lancet 2003, 362:1542-1547.
75. Fremeaux-Bacchi V, Moulton EA, Kavanagh D, Dragon-Durey MA, Blouin J,
Caudy A, Arzouk N, Cleper R, Francois M, Guest G, Pourrat J, Seligman R,
Fridman WH, Loirat C, Atkinson JP: Genetic and functional analyses of
membrane cofactor protein (CD46) mutations in atypical hemolytic
uremic syndrome. J Am Soc Nephrol 2006, 17:2017-2025.
76. Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J, Vigneau C, Kuypers D,
Boudailliez B, Loirat C, Rondeau E, Fridman WH: Complement factor I: a
susceptibility gene for atypical haemolytic uraemic syndrome. J Med
Genet 2004, 41:e84.
77. Kavanagh D, Kemp EJ, Mayland E, Winney RJ, Duffield JS, Warwick G,
Richards A, Ward R, Goodship JA, Goodship TH: Mutations in complement
factor I predispose to development of atypical hemolytic uremic
syndrome. J Am Soc Nephrol 2005, 16:2150-2155.
78. Kavanagh D, Richards A, Noris M, Hauhart R, Liszewski MK, Karpman D,
Goodship JA, Fremeaux-Bacchi V, Remuzzi G, Goodship TH, Atkinson JP:
Characterization of mutations in complement factor I (CFI) associated
with hemolytic uremic syndrome. Mol Immunol 2008, 45:95-105.
79. Nillson SC, Nilsson SC, Kalchishkova N, Trouw LA, Fremeaux-Bacchi V,
Villoutreix BO, Blom AM: Mutations in complement factor I as found in
atypical hemolytic uremic syndrome lead either to altered secretion or
altered function of factor I. Eur J Immunol 2010, 40:172-185.
80. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA,
Garrido CA, López-Trascasa M, Sánchez-Corral P, Morgan BP, Rodríguez de
Córdoba S: Gain-of-function mutations in complement factor B are
associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci
USA 2007, 104:240-245.
81. Roumenina LT, Jablonski M, Hue C, Blouin J, Dimitrov JD, Dragon-
Durey MA, Cayla M, Fridman WH, Macher MA, Ribes D, Moulonguet L,
Rostaing L, Satchell SC, Mathieson PW, Sautes-Fridman C, Loirat C,
Regnier CH, Halbwachs-Mecarelli L, Fremeaux-Bacchi V: Hyperfunctional C3
convertase leads to complement deposition on endothelial cells and
contributes to atypical hemolytic uremic syndrome. Blood 2009,
114:2837-2845.
82. Tawadrous H, Maga T, Sharma J, Kupferman J, Smith RJ, Schoeneman M: A
novel mutation in the complement factor B gene (CFB) and atypical
hemolytic uremic syndrome. Pediatr Nephrol 2010, 25:947-951.
83. Fremeaux-Bacchi V, Miller EC, Liszewski MK, Strain L, Blouin J, Brown AL,
Moghal N, Kaplan BS, Weiss RA, Lhotta K, Kapur G, Mattoo T, Nivet H,
Wong W, Gie S, Hurault de Ligny B, Fischbach M, Gupta R, Hauhart R,
Meunier V, Loirat C, Dragon-Durey MA, Fridman WH, Janssen BJ,
Goodship TH, Atkinson JP: Mutations in complement C3 predispose to
development of atypical hemolytic uremic syndrome. Blood 2008,
112:4948-4952.
84. Lhotta K, Janecke AR, Scheiring J, Petzlberger B, Giner T, Fally V, Würzner R,
Zimmerhackl LB, Mayer G, Fremeaux-Bacchi V: A large family with a gain-
of-function mutation of complement C3 predisposing to atypical
hemolytic uremic syndrome, microhematuria, hypertension and chronic
renal failure. Clin J Am Soc Nephrol 2009, 4:1356-1362.
85. Esparza-Gordillo J, Jorge EG, Garrido CA, Carreras L, López-Trascasa M,
Sánchez-Corral P, de Córdoba SR: Insights into hemolytic uremic
syndrome: Segregation of three independent predisposition factors in a
large, multiple affected pedigree. Mol Immunol 2006, 43:1769-1775.
86. Fremeaux-Bacchi V, Kemp EJ, Goodship JA, Dragon-Durey MA, Strain L,
Loirat C, Deng HW, Goodship TH: The development of atypical HUS is
influenced by susceptibility factors in factor H and membrane cofactor
protein-evidence from two independent cohorts. J Med Genet 2005,
42:852-856.
87. Caprioli J, Castelletti F, Bucchioni S, Bettinaglio P, Bresin E, Pianetti G,
Gamba S, Brioschi S, Daina E, Remuzzi G, Noris M, International Registry of
Recurrent and Familial HUS/TTP: Complement factor H mutations and
gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the
A2089G and the G2881T polymorphisms are strongly associated with
the disease. Hum Mol Genet 2003, 12:3385-3395.
88. Abarrategui-Garrido C, Martínez-Barricarte R, López-Trascasa M, de
Córdoba SR, Sánchez-Corral P: Characterization of complement factor H-
related (CFHR) proteins in plasma reveals novel genetic variations of
CFHR1 associated with atypical hemolytic uremic syndrome. Blood 2009,
114:4261-4271.
89. Blom AM, Bergström F, Edey M, Diaz-Torres M, Kavanagh D, Lampe A,
Goodship JA, Strain L, Moghal N, McHugh M, Inward C, Tomson C,
Frémeaux-Bacchi V, Villoutreix BO, Goodship TH: A novel non-synonymous
polymorphism (p.Arg240His) in C4b-binding protein is associated with
atypical hemolytic uremic syndrome and leads to impaired alternative
pathway cofactor activity. J Immunol 2008, 180:6385-6391.
90. Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C,
Pecoraro C, Tylor C, Van De Kar N, Van De Wall J, Zimmerhackl L:
Guidelines for the investigation and initial therapy of diarrhea
negative haemolytic uraemic syndrome. Pediatr Nephrol 2009,
24:687-696.
91. Taylor CM, Machin S, Wigmore SJ, Goodship TH: Clinical Practice
Guidelines for the management of atypical Haemolytic Uraemic
Syndrome in the United Kingdom. Br J Haematol 2010, 148:37-47.
92. Huang DT, Chi H, Lee HC, Chiu NC, Huang FY: T-antigen activation for
prediction of pneumococcus-induced hemolytic uremic syndrome and
hemolytic anemia. Pediatr Infect Dis J 2006, 25:608-610.
93. Waters AM, Kerecuk L, Luk D, Haq MR, Fitzpatrick MM, Gilbert RD, Inward C,
Jones C, Pichon B, Reid C, Slack MP, Van’t Hoff W, Dillon MJ, Taylor CM,
Tullus K: Hemolytic uremic syndrome associated with invasive
pneumococcal disease: the United Kingdom experience. J Pediatr 2007,
151:140-144.
94. Copelovitch L, Kaplan BS: Streptococcus pneumoniae-associated
hemolytic uremic syndrome. Pediatr Nephrol 2008, 23:1951-1956.
95. Loirat C, Girma JP, Desconclois C, Coppo P, Veyradier A: Thrombotic
thrombocytopenic purpura related to severe ADAMTS13 deficiency in
children. Pediatr Nephrol 2009, 24:19-29.
Loirat and Frémeaux-Bacchi Orphanet Journal of Rare Diseases 2011, 6:60
http://www.ojrd.com/content/6/1/60
Page 27 of 3096. Noris M, Bucchioni S, Galbusera M, Donadelli R, Bresin E, Castelletti F,
Caprioli J, Brioschi S, Scheiflinger F, Remuzzi G, International Registry of
Recurrent and Familial HUS/TTP: Complement factor H mutation in
familial thrombotic thrombocytopenic purpura with ADAMTS13
deficiency and renal involvement. J Am soc Nephrol 2005, 16:1177-1183.
97. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T: FRETS-VWF73, a first
fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005,
129:93-100.
98. Bouts AH, Roofthooft MT, Salomons GS, Davin JC: CD46-associated atypical
hemolytic uremic syndrome with uncommon course caused by cblC
deficiency. Pediatr Nephrol 2010, 25:2547-2548.
99. Guigonis V, Frémeaux-Bacchi V, Giraudier S, Favier R, Borderie D, Massy Z,
Mougenot B, Rosenblatt DS, Deschênes G: Late-onset thrombocytic
microangiopathy caused by cblC disease: association with a factor H
mutation. Am J Kidney Dis 2005, 45:588-595.
100. Fakhouri F, Jablonski M, Lepercq J, Blouin J, Benachi A, Hourmant M,
Pirson Y, Dürrbach A, Grünfeld JP, Knebelmann B, Frémeaux-Bacchi V:
Factor H, membrane cofactor protein, and factor I mutations in patients
with hemolysis, elevated liver enzymes, and low platelet count
syndrome. Blood 2008, 112:4542-4545.
101. Le Quintrec M, Lionet A, Kamar N, Karras A, Barbier S, Buchler M, Fakhouri F,
Provost F, Fridman WH, Thervet E, Legendre C, Zuber J, Frémeaux-Bacchi V:
Complement mutationassociated de novo thrombotic microangiopathy
following kidney transplantation. Am J Transplant 2008, 8:1694-1701.
102. Salmon JE, Heuser C, Triebwasser M, Liszewski MK, Kavanagh D,
Roumenina L, Branch DW, Goodship T, Fremeaux-Bacchi V, Atkinson JP:
Mutations in Complement Regulatory Proteins Predispose to
Preeclampsia: A Genetic Analysis of the PROMISSE Cohort. PLoS Med
2011, 8:e1001013.
103. Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T: Plasmatherapy in atypical
hemolytic uremic syndrome. Semin Thromb Hemost 2010, 36:673-681.
104. Pichette V, Quérin S, Schürch W, Brun G, Lehner-Netsch G, Delâge JM:
Familial hemolyticuremic syndrome and homozygous factor H
deficiency. Am J Kidney Dis 1994, 24:936-941.
105. Landau D, Shalev H, Levy-Finer G, Polonsky A, Segev Y, Katchko L: Familial
hemolytic uremic syndrome associated with complement factor H
deficiency. J Pediatr 2001, 138:412-417.
106. Nathanson S, Frémeaux-Bacchi V, Deschênes G: Successful plasma therapy
in hemolytic uremic syndrome with factor H deficiency. Pediatr Nephrol
2001, 16:554-556.
107. Nathanson S, Ulinski T, Frémeaux-Bacchi V, Deschênes G: Secondary failure
of plasma therapy in factor H deficiency. Pediatr Nephrol 2006,
21:1769-1771.
108. Licht C, Weyersberg A, Heinen S, Stapenhorst L, Devenge J, Beck B,
Waldherr R, Kirschfink M, Zipfel PF, Hoppe B: Successful plasma therapy
for atypical hemolytic uremic syndrome caused by factor H deficiency
owing to a novel mutation in the complement cofactor protein domain
15. Am J Kidney Dis 2005, 45:415-421.
109. Cho HY, Lee BS, Moon KC, Ha IS, Cheong HI, Choi Y: Complete factor H
deficiencyassociated atypical hemolytic uremic syndrome in a neonate.
Pediatr Nephrol 2007, 22:874-880.
110. Stratton JD, Warwicker P: Successful treatment of factor H-related
haemolytic uraemic syndrome. Nephrol Dial Transplant 2002, 17:684-685.
111. Gerber A, Kirchhoff-Moradpour AH, Obieglo S, Brandis M, Kirschfink M,
Zipfel PF, Goodship JA, Zimmerhackl LB: Successful (?) therapy of
hemolytic-uremic syndrome with factor H abnormality. Pediatr Nephrol
2003, 18:952-955.
112. Filler G, Radhakrishnan S, Strain L, Hill A, Knoll G, Goodship TH: Challenges
in the management of infantile factor H associated hemolytic uremic
syndrome. Pediatr Nephrol 2004, 19:908-11.
113. Davin JC, Strain L, Goodship THJ: Plasma therapy in atypical haemolytic
uremic syndrome: lessons from a family with a factor H mutation.
Pediatr Nephrol 2008, 23:1517-1521.
114. Lapeyraque AL, Wagner E, Phan V, Clermont MJ, Merouani A, Frémeaux-
Bacchi V, Goodship TH, Robitaille P: Efficacy of plasma therapy in atypical
hemolytic uremic syndrome with complement factor H mutations.
Pediatr Nephrol 2008, 8:1363-1366.
115. De S, Waters AM, Segal AO, Trautmann A, Harvey EA, Licht C: Severe
atypical HUS caused by CFH S1191L-case presentation and review of
treatment options. Pediatr Nephrol 2010, 25:97-104.
116. Ohali M, Shalev H, Schlesinger M, Katz Y, Kachko L, Carmi R, Sofer S,
Landau D: Hypocomplementemic autosomal recessive hemolytic uremic
syndrome with decreased factor H. Pediatr Nephrol 1998, 12:619-624.
117. Abarrategui-Garrido C, Melgosa M, Peña-Carrión A, de Jorge EG, de
Córdoba SR, López-Trascasa M, Sánchez-Corral P: Mutations in proteins of
the alternative pathway of complement and the pathogenesis of
atypical hemolytic uremic syndrome. Am J Kidney Dis 2008, 52:171-180.
118. Sethi SK, Dragon-Durey MA, Thaker N, Hari P, Bagga A: Hemolytic uremic
syndrome due to homozygous factor H deficiency. Clin Exp Nephrol 2009,
13:526-530.
119. Nilsson SC, Karpman D, Vaziri-Sani F, Kristoffersson AC, Salomon R, Provot F,
Fremeaux-Bacchi V, Trouw LA, Blom AM: A mutation in factor I that is
associated with atypical hemolytic uremic syndrome does not affect the
function of factor I in complement regulation. Mol Immunol 2007,
44:1835-1844.
120. Davin JC, Buter N, Groothoff J, van Wijk J, Bouts A, Strain L, Goodship T:
Prophylactic plasma exchange in CD46-associated atypical haemolytic
uremic syndrome. Pediatr Nephrol 2009, 24:1757-1760.
121. Chatelet V, Frémeaux-Bacchi V, Lobbedez T, Ficheux M, de Ligny BH: Safety
and long-term efficacy of eculizumab in a renal transplant patient with
recurrent atypical hemolytic-uremic syndrome. Am J Transplant 2009,
9:2644-2645.
122. Kwon T, Dragon-Durey MA, Macher MA, Baudouin V, Maisin A,
Peuchmaur M, Fremeaux-Bacchi V, Loirat C: Successful pre-transplant
management of a patient with anti-factor H autoantibodies-associated
haemolytic uraemic syndrome. Nephrol Dial Transplant 2008, 23:2088-2090.
123. Lionet A, Provot F, Glowacki F, Veronique Fremeaux-Bacchi V, Hazzan M: A
case of adult atypical haemolytic uraemic syndrome related to anti-
factor H autoantibodies successfully treated by plasma exchange,
corticosteroids and rituximab. NDT Plus 2009, 2:458-460.
124. Boyer O, Balzamo E, Charbit M, Biebuyck-Gougé N, Salomon R, Dragon-
Durey MA, Frémeaux-Bacchi V, Niaudet P: Pulse cyclophosphamide
therapy and clinical remission in atypical hemolytic uremic syndrome
with anti-complement factor H autoantibodies. Am J Kidney Dis 2010,
55:923-927.
125. Saland JM, Ruggenenti P, Remuzzi G, Consensus Study Group: Liver-kidney
transplantation to cure atypical hemolytic uremic syndrome. J Am Soc
Nephrol 2009, 20:940-949.
126. Michon B, Moghrabi A, Winikoff R, Barrette S, Bernstein ML, Champagne J,
David M, Duval M, Hume HA, Robitaille N, Bélisle A, Champagne MA:
Complications of apheresis in children. Transfusion 2007, 47:1837-1842.
127. Witt V, Stegmayr B, Ptak J, Wikström B, Berlin G, Axelsson CG, Griskevicius A,
Centoni PE, Liumbruno GM, Molfettini P, Audzijoniene J, Mokvist K,
Sojka BN, Norda R, Ramlow W, Blaha M, Evergren M, Tomaz J: World
apheresis registry data from 2003 to 2007, the pediatric and adolescent
side of the registry. Transfus Apher Sci 2008, 39:255-260.
128. Bresin E, Daina E, Noris M, Castelletti F, Stefanov R, Hill P, Goodship HT,
Remuzzi G: Outcome of renal transplantation in patients with Non-Shiga-
Toxin associated hemolytic syndrome: prognostic significance of genetic
background. Clin J Am Soc Nephrol 2006, 1:88-99.
129. Loirat C, Fremeaux-Bacchi V: Hemolytic uremic syndrome recurrence after
renal transplantation. Pediatr Transpl 2008, 12:619-629.
130. Noris M, Remuzzi G: Thrombotic microangiopathy after kidney
transplantation. Am J Transplant 2010, 10:1517-1523.
131. Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Frémeaux-Bacchi V,
Legendre C: New insights into postrenal transplant hemolytic uremic
syndrome. Nat Rev Nephrol 2011, 7:23-35.
132. Chan MR, Thomas CP, Torrealba JR, Djamali A, Fernandez LA, Nishimura CJ,
Smith RJ, Samaniego MD: Recurrent atypical hemolytic uremic syndrome
associated with factor I mutation in a living related renal transplant
recipient. Am J Kidney Dis 2009, 53:321-326.
133. Le Quintrec M, Zuber J, Noel LH, Thervet E, Frémeaux-Bacchi V, Niaudet P,
Fridman WH, Legendre C, Dragon-Durey MA: Anti-Factor H autoantibodies
in a fifth renal transplant recipient with atypical hemolytic and uremic
syndrome. Am J Transplant 2009, 9:1223-1229.
134. Waters AM, Pappworth I, Marchbank K, Bockenhauer D, Tullus K,
Pickering MC, Strain L, Sebire N, Shroff R, Marks SD, Goodship TH, Rees L:
Successful renal transplantation in factor H autoantibody associated
HUS with CFHR1 and 3 deficiency and CFH variant G2850T. Am J
Transplant 2010, 10:168-172.
Loirat and Frémeaux-Bacchi Orphanet Journal of Rare Diseases 2011, 6:60
http://www.ojrd.com/content/6/1/60
Page 28 of 30135. Oyen O, Strøm EH, Midtvedt K, Bentdal O, Hartmann A, Bergan S, Pfeffer P,
Brekke IB: Calcineurin inhibitor-free immunosuppression in renal allograft
recipients with thrombotic microangiopathy/hemolytic uremic
syndrome. Am J Transplant 2006, 6:412-418.
136. Hirt-Minkowski P, Schaub S, Mayr M, Schifferli JA, Dickenmann M,
Frémeaux-Bacchi V, Steiger J: Haemolytic uraemic syndrome caused
by factor H mutation: is single kidney transplantation under
intensive plasmatherapy an option? N e p h r o lD i a lT r a n s p l a n t2009,
24:3548-3551.
137. Davin JC, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T:
Maintenance of Kidney Function Following Treatment With Eculizumab
and Discontinuation of Plasma Exchange After a Third Kidney Transplant
for Atypical Hemolytic Uremic Syndrome Associated With a CFH
Mutation. Am J Kidney Dis 2010, 55:708-711.
138. Albertazzi V, Bonucchi D, De Amicis S, Americo C, Ghiandai G, Cappelli G: A
favorable 3-year outcome of kidney transplantation in atypical
hemolytic uremic syndrome associated with a factor H mutation: case
report. Transplant Proc 2010, 42:1352-1354.
139. Cruzado JM, de Córdoba SR, Melilli E, Bestard O, Rama I, Sánchez-Corral P,
López-Trascasa M, Navarro I, Torras J, Gomà M, Grinyó JM: Successful renal
transplantation in a patient with atypical hemolytic uremic syndrome
carrying mutations in both factor I and MCP. Am J Transplant 2009,
9:1477-1483.
140. Remuzzi G, Ruggenenti P, Codazzi D, Noris M, Caprioli J, Locatelli G,
Gridelli B: Combined kidney and liver transplantation for familial
haemolytic uraemic syndrome. Lancet 2002, 359:1671-1672.
141. Remuzzi G, Ruggenenti P, Colledan M, Gridelli B, Bertani A, Bettinaglio P,
Bucchioni S, Sonzogni A, Bonanomi E, Sonzogni V, Platt JL, Perico N,
Noris M: Hemolytic uremic syndrome: a fatal outcome after kidney and
liver transplantation performed to correct factor h gene mutation. Am J
Transplant 2005, 5:1146-1150.
142. Cheong HI, Lee BS, Kang HG, Hahn H, Suh KS, Ha IS, Choi Y: Attempted
treatment of factor H deficiency by liver transplantation. Pediatr Nephrol
2004, 19:454-458.
143. Saland JM, Emre SH, Shneider BL, Benchimol C, Ames S, Bromberg JS,
Remuzzi G, Strain L, Goodship TH: Favorable long-term outcome after
liver-kidney transplant for recurrent hemolytic uremic syndrome
associated with a factor H mutation. Am J Transplant 2006,
6:19481952.
144. Jalanko H, Peltonen S, Koskinen A, Puntila J, Isoniemi H, Holmberg C,
Pinomäki A, Armstrong E, Koivusalo A, Tukiainen E, Mäkisalo H, Saland J,
Remuzzi G, de Cordoba S, Lassila R, Meri S, Jokiranta TS: Successful liver-
kidney transplantation in two children with aHUS caused by a mutation
in complement factor H. Am J Transplant 2008, 8:216-221.
145. Saland JM, Shneider BL, Bromberg JS, Shi PA, Ward SC, Magid MS,
Benchimol C, Seikaly MG, Emre SH, Bresin E, Remuzzi G: Successful split
liver-kidney transplant for factor H associated hemolytic uremic
syndrome. Clin J Am Soc Nephrol 2009, 4:201-206.
146. Haller W, Milford DV, Goodship TH, Sharif K, Mirza DF, McKiernan PJ:
Successful Isolated Liver Transplantation in a Child with Atypical
Hemolytic Uremic Syndrome and a Mutation in Complement Factor H.
Am J Transplant 2010, 10:2142-2147.
147. Wilson C, Torpey N, Jaques B, Strain L, Talbot D, Manas D, Goodship T:
Successful simultaneous liver-kidney transplant in an adult with atypical
hemolytic uremic syndrome associated with a mutation in complement
factor H. Am J Kidney Dis 2011, 58:109-112.
148. Salant DJ: Targeting Complement C5 in Atypical Hemolytic Uremic
Syndrome. J Am Soc Nephrol 2011, 22:7-9.
149. Brodsky RA: Advances in the diagnosis and therapy of paroxysmal
nocturnal hemoglobinuria. Blood Rev 2008, 22:65-74.
150. Parker C: Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet
2009, 373:759767.
151. Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M,
Mitchell LD, Cohen DR, Gregory WM, Hillmen P: Long-term treatment with
eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy
and improved survival. Blood 2011, 117:6786-6792.
152. Rosales A, Riedl M, Zimmerhackl LB: Thrombotic microangiopathy: atypical
HUS: current diagnostic and therapeutic approaches. Nat Rev Nephrol
2010, 6:504-506.
153. Waters AM, Licht C: aHUS caused by complement dysregulation: new
therapies on the horizon. Pediatr Nephrol 2011, 26:41-57.
154. Ram S, Lewis LA, Rice PA: Infections of people with complement
deficiencies and patients who have undergone splenectomy. Clin
Microbiol Rev 2010, 23:740-780.
155. Gruppo RA, Rother RP: Eculizumab for congenital atypical hemolytic-
uremic syndrome. N Engl J Med 2009, 360:544-546.
156. Fremont OT, Gordon CA, Hand MM: Eculizumab treatment for aHUS in a
child with positive family history. PUB715, 42nd Annual Meeting of the
American Society of Nephrology, San Diego, California, USA 2009.
157. Mache CJ, Acham-Roschitz B, Frémeaux-Bacchi V, Kirschfink M, Zipfel PF,
Roedl S, Vester U, Ring E: Complement inhibitor eculizumab in atypical
hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009, 4:1312-1316.
158. Köse O, Zimmerhackl LB, Jungraithmayr T, Mache C, Nürnberger J: New
treatment options for atypical hemolytic uremic syndrome with the
complement inhibitor eculizumab. Semin Thromb Hemost 2010,
36:669-672.
159. Lapeyraque AL, Frémeaux-Bacchi V, Robitaille P: Efficacy of eculizumab in a
patient with factor-H-associated atypical hemolytic uremic syndrome.
Pediatr Nephrol 2011, 26:621-624.
160. Prescott HC, Wu HM, Cataland SR, Baiocchi RA: Eculizumab therapy in an
adult with plasma exchange-refractory atypical hemolytic uremic
syndrome. Am J Hematol 2010, 5:976-977.
161. Ohanian M, Cable C, Halka K: Eculizumab safely reverses neurologic
impairment and eliminates need for dialysis in severe atypical
haemolytic uremic syndrome. Clin Pharmacology: Advances and
Applications 2011, 3:5-12.
162. Nürnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba HA,
Kribben A, Zimmerhackl LB, Janecke AR, Nagel M, Kirschfink M: Eculizumab
for atypical hemolytic-uremic syndrome. N Engl J Med 2009, 360:542-544.
163. Châtelet V, Lobbedez T, Frémeaux-Bacchi V, Ficheux M, Ryckelynck JP,
Hurault de Ligny B: Eculizumab: safety and efficacy after 17 months of
treatment in a renal transplant patient with recurrent atypical
hemolytic-uremic syndrome: case report. Transplant Proc 2010,
42:4353-4355.
164. Legault DJ, Boelkins MR: Successful treatment of aHUS recurrence and
arrest of plasma exchange resistant TMA post-renal transplantation with
the terminal complement inhibitor eculizumab. Poster 2421, 51st Meeting
of the American Society of Hematology, New Orleans, LA, USA 2009.
165. Larrea CF, Cofan F, Oppenheimer F, Campistol JM, Escolar G, Lozano M:
Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-
uremic syndrome after renal transplantation. Transplantation 2010,
89:903-904.
166. Al-Akash SI, Almond PS, Savell VH Jr, Gharaybeh SI, Hogue C: Eculizumab
induces longterm remission in recurrent post-transplant HUS associated
with C3 gene mutation. Pediatr Nephrol 2011, 26:613-619.
167. Zimmerhackl LB, Hofer J, Cortina G, Mark W, Wurzner R, Jungraithmayr TC,
Khursigara G, Kliche KO, Radauer W: Prophylactic eculizumab after renal
transplantation in atypical hemolytic-uremic syndrome. N Engl J Med
2010, 362:1746-1748.
168. Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S: Prophylactic
eculizumab prior to kidney transplantation for atypical hemolytic uremic
syndrome. Pediatr Nephrol 2011, 26:1325-1329.
169. Nester C, Stewart Z, Myers D, Jetton J, Nair R, Reed A, Thomas C, Smith R,
Brophy P: Pre-emptive Eculizumab and Plasmapheresis for Renal
Transplant in Atypical Hemolytic Uremic Syndrome. Clin J Am Soc
Nephrol 2011, 6:1488-1494.
170. Legendre C, Babu S, Furman RR, Sheerin NS, Cohen DJ, Gaber AO, Eitner F,
Delmas Y, Loirat c, Greenbaum LA, Zimmerhackl LB: Safety and efficacy of
Eculizumab in aHUS resistant to plasma Therapy: interim analysis from a
Phase II trial. FC 406, 43rd Annual Meeting of the American Society of
Nephrology, Denver, CO, USA 2010, 16-21.
171. Muus P, Legendre C, Douglas K, Hourmant M, Delmas Y, Herthelius BM,
Trivelli A, Loirat C, Goodship TH, Licht C: Safety and efficacy of eculizumab
in aHUS patients on chronic plasma therapy: Interim analysis of a phase
II trial. Poster 1274, 43rd Annual Meeting of the American Society of
Nephrology, Denver, CO, USA 2010, 16-21.
172. List of the various Open Label Multicenter Trials of Eculizumab In
Atypical Hemolytic Uremic Syndrome. [http://clinicaltrials.gov].
173. Emlen W, Li W, Kirschfink M: Therapeutic complement inhibition: new
developments. Semin Thromb Hemost 2010, 36:660-668.
174. Fakhouri F, de Jorge EG, Brune F, Azam P, Cook HT, Pickering MC:
Treatment with human complement factor H rapidly reverses renal
Loirat and Frémeaux-Bacchi Orphanet Journal of Rare Diseases 2011, 6:60
http://www.ojrd.com/content/6/1/60
Page 29 of 30complement deposition in factor H-deficient mice. Kidney Int 2010,
78:279-286.
175. Schmidt CQ, Slingsby FC, Richards A, Barlow PN: Production of biologically
active complement factor H in therapeutically useful quantities. Protein
Expr Purif 2011, 76:254-263.
176. Büttner-Mainik A, Parsons J, Jérôme H, Hartmann A, Lamer S, Schaaf A,
Schlosser A, Zipfel PF, Reski R, Decker EL: Production of biologically active
recombinant human factor H in Physcomitrella. Plant Biotechnol J 2011,
9:373-383.
177. Loirat C, Macher MA, Elmaleh-Berges M, Kwon T, Deschênes G,
Goodship TH, Majoie C, Davin JC, Blanc R, Savatovsky J, Moret J, Fremeaux-
Bacchi V: Non-atheromatous arterial stenoses in atypical haemolytic
uraemic syndrome associated with complement dysregulation. Nephrol
Dial Transplant 2010, 25:3421-3425.
178. Davin JC, Majoie C, Groothoff J, Gracchi V, Bouts A, Goodship TH, Loirat C:
Prevention of large-vessel stenoses in atypical hemolytic uremic
syndrome associated with complement dysregulation. Pediatr Nephrol
2011, 26:155-157.
doi:10.1186/1750-1172-6-60
Cite this article as: Loirat and Frémeaux-Bacchi: Atypical hemolytic
uremic syndrome. Orphanet Journal of Rare Diseases 2011 6:60.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Loirat and Frémeaux-Bacchi Orphanet Journal of Rare Diseases 2011, 6:60
http://www.ojrd.com/content/6/1/60
Page 30 of 30